



CORPORATE **SUPPORTERS**

The ASN Corporate Support Program recognizes supporters year round for their generous contributions to the Society. Through this program, supporters help ASN lead the fight against kidney diseases. ASN gratefully acknowledges the following companies for their contributions in 2024.

DIAMOND LEVEL











PLATINUM LEVEL















GOLD LEVEL

Mallinckrodt

Vertex Pharmaceuticals

SILVER LEVEL

CorMedix

CSI Vifor

Genentech, a member of the Roche Group

GSK

Medtronic

Natera

BRONZE LEVEL

Apellis Pharmaceuticals

Boehringer Ingelheim Pharmaceuticals, Inc.

Lilly USA

Unicycive Therapeutics Inc. Veloxis Pharmaceuticals Zvdus Lifesciences

Table of Contents

Kidney Week Mobile App	. 2
Welcome	. 3
Schedule-at-a-Glance	4
Accreditation, CE Credits, MOC Points	6
Certificates of Attendance for International Participants	. 7
Day-at-a-Glance: Wednesday, October 23 (Early Programs)	. 9
Day-at-a-Glance: Thursday, October 24	12
Day-at-a-Glance: Friday, October 25	26
Day-at-a-Glance: Saturday, October 26	42
Scientific Exposition: October 24-26	53
Exhibitor Spotlights: October 24-26	54
Day-at-a-Glance: Sunday, October 27	56

Attention US Health Professionals

To ensure full compliance with the Open Payments (Physician Payments Sunshine Act), a provision of the Patient Protection and Affordable Care Act (PL 111-148) that requires applicable manufacturers and applicable group purchasing organizations to report financial payments made to US physicians and select other US healthcare professionals, including as part of supported ASN activities. ASN reserves the right to provide information to such entities about US physicians, US physician assistants, and US advanced practice nurses (and their spouses) who participate in selected ASN activities.

Section 6002 of the Affordable Care Act requires the establishment of a transparency program, now known as Open Payments. The program increases public awareness of financial relationships between drug and device manufacturers and certain health care providers. ASN makes reasonable attempts to collect and maintain the following information about its US physician members: 1) name and business address, 2) specialty, 3) National Provider Identification (NPI) number, and 4) state(s) professional license number and name of state(s) issuing license.

In the event that ASN receives payment from an applicable sponsor and the sponsor requests the reportable information from ASN, ASN will provide the information under the condition that the sponsor agrees to use the data only for reporting purposes covered under the Act and no other purpose.

US physicians have certain rights under this Act, and more information about these rights can be found at the resources listed below.

To learn more, please go to the US Government's Center for Medicare & Medicaid Services (CMS) website, www.cms.gov/openpayments. Additional information can be found at the American Medical Association's website.

American Society of Nephrology www.asn-online.org 1401 H Street, NW | Suite 900 Washington, DC 20005 Copyright © 2024 ASN

Download the Kidney Week Mobile App

Navigate the meeting like a pro with the meeting mobile app.

- Stay organized with current session, exhibitor, and meeting information.
- Receive important realtime communications from ASN.
- Build a personalized schedule and bookmark exhibitors.
- Stay in-the-know and join the social media conversation.
- And more!





GET THE FREE APP SEARCH FOR "ASN KIDNEY WEEK"







The Kidney Week Mobile App is supported by



Welcome to ASN Kidney Week 2024

ASN proudly welcomes you to Kidney Week, the world's premier nephrology meeting. At Kidney Week, the world's leading experts share new approaches to health care, research, education, and policy. Participants have opportunities to network with fellow specialists, advance careers, learn best practices for treating and improving the lives of people with kidney diseases, and collaborate with colleagues from around the world.

Leading the fight against kidney diseases for over 50 years, ASN represents health professionals whose intellectual rigor, integrity, and ingenuity advance kidney research, treatment, and policy and improve the lives of millions of patients.

ASN Council

Deidra C. Crews, MD, ScM, FASN, *President*Michelle A. Josephson, MD, FASN, *Past President*Prabir Roy-Chaudhury, MD, PhD, FASN, *President-Elect*Samir M. Parikh, MD, FASN, *Secretary*

Kidney Week Education Committee

Rasheed A. Gbadegesin, MBBS, MD, FASN, Co-Chair Tamara Isakova, MD, MMSc, Co-Chair Matthew K. Abramowitz, MD, MS, FASN Nisha Bansal, MD, FASN Erin F. Barreto, MS, PharmD, FASN Whitney Besse, MD Subhashini Bolisetty, PhD Edwina A. Brown, MBChB, MD Corey J. Cavanaugh, DO David Cherney, MD, PhD Jordana B. Cohen, MD, MS, FASN Ilse S. Daehn, PhD, FASN Erica Davis, PhD Lorenzo G. Gallon, MD Gentzon Hall, MD, PhD, FASN Takashi Hato, MD Leal C. Herlitz, MD Michael Heung, MD, MS, FASN

Jeffrey H. Miner, PhD, FASN, *Treasurer* Jeffrey S. Berns, MD, FASN, *Councilor* Linda F. Fried, MD, MPH, FASN, *Councilor* Patrick H. Nachman, MD, FASN, *Councilor* Daniel E. Weiner, MD, MS, FASN, *Councilor*

Annet Kirabo, MS, PhD, DVM Benjamin S. Ko, MD Matthias Kretzler, MD Keisa Mathis, PhD Rosa M.A. Moyses, MD, PhD Monika A. Niewczas, MD, PhD, MPH Kalani L. Raphael, MD, MS, FASN Timothy Ray, CNN, CNN-NP, DNP, NP Kimberly J. Reidy, MD Avi Z. Rosenberg, MD, PhD Tammy L. Sirich, MD, FASN Arohan R. Subramanya, MD, FASN Katherine R. Tuttle, MD, FASN Smitha R. Vidi, MD Monnie Wasse, MD, MPH, FASN David M. White Alexander C. Wiseman, MD Anna L. Zisman, MD, FASN


Schedule-at-a-Glance

	1				l e						ı	ı
Thursday, October 24	AM	6:30	7:00	7:30	8:00	8:30	9:00	9:30	10:00	10:30	11:00	11:30
Plenary Session												
BCSS, CPS, TS, SS												
Educational Symposia												
Oral Abstract Sessions												
Poster Sessions									Ask	the A	utho	r
Scientific Exposition									Exhi	ibitor	Spot	lights
Friday, October 25	АМ	6:30	7:00	7:30	8:00	8:30	9:00	9:30	10:00	10:30	11:00	11:30
Plenary Session												
BCSS, CPS, TS, SS												
Educational Symposia												
Oral Abstract Sessions										High Clini	-Impa cal Tr	act ials
Poster Sessions									Ask	the A	utho	r
Scientific Exposition									Exhibitor Spotlights			
Saturday, October 26	АМ	6:30	7:00	7:30	8:00	8:30	9:00	9:30	10:00	10:30	11:00	11:30
Plenary Session												
BCSS, CPS, TS, SS												
Educational Symposia												
Oral Abstract Sessions										High Clini	-Impa cal Tr	act ials
Poster Sessions										he Au rainee		
Scientific Exposition									Exhi	bitor	Spotl	ights
Sunday, October 27	АМ	6:30	7:00	7:30	8:00	8:30	9:00	9:30	10:00	10:30	11:00	11:30
Plenary Session and ASN Business Meeting												
BCSS, CPS, TS, SS												

LEGEND

BCSS - Basic/Clinical Science Sessions CPS - Clinical Practice Sessions TS - Translational Sessions

SS - Special Sessions



Accreditation, CE Credits, and MOC Points(Annual Meeting, October 24-27)

Learning Objectives

At the conclusion of this activity, participants will have increased knowledge in the field of nephrology and will be able to:

- 1. Identify recent discoveries in basic, translational, and clinical research in nephrology.
- 2. Construct new research questions based on updated scientific and clinical advances in nephrology-related disciplines.
- Translate recent advances in the areas of general nephrology, dialysis, transplantation, and hypertension into new standards and approaches to clinical care of patients with kidney diseases and related disorders.

Target Audience

- Physicians
- PhDs and Other Researchers
- Medical and Other Trainees—including medical students, residents, graduate students, post-docs, and fellows
- Nurses and Nurse Practitioners
- Pharmacists
- Physician Assistants
- Other Health Care Professionals

Accreditation Statement

In support of improving patient care, the American Society of Nephrology is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



Continuing Medical Education Credits

AMA CREDIT DESIGNATION STATEMENT - PHYSICIANS

The American Society of Nephrology designates this blended learning activity for a maximum of 75.0 AMA PRA Category 1 Credits $^{\text{TM}}$. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ANCC CREDIT DESIGNATION STATEMENT – NURSES This CE activity is approved for 75.0 ANCC contact hours.

ACPE CREDIT DESIGNATION STATEMENT – PHARMACISTS This activity has been approved for 75.0 contact hours.

AAPA/NCCPA CREDIT DESIGNATION STATEMENT – PHYSICIAN ASSISTANTS NCCPA accepts Certificates of Participation for activities that are certified for *AMA PRA Category 1 Credit*™. In accordance with AAPA/NCCPA and AMA guidelines, Physician Assistants may receive a Certificate of Participation that states this activity has been approved for up to 75.0 *AMA PRA Category 1 Credits*™.



ASN values each participant's review and comments on the quality of ASN's educational activities. Please complete the evaluation, claim credits, and claim MOC at www.asn-online.org/elearning by December 18, 2024. Instructions are available on the ASN website and at ASN Services in Lobby C of the convention center.

Note: For Early Program credits, please refer to the program materials.

Maintenance of Certification (MOC) Points

The Kidney Week Annual Meeting offers MOC Points for American Board of Internal Medicine (ABIM) and American Board of Pediatrics (ABP) Diplomates with the completion of a reflective statement and commitment-to-change questions in this activity's evaluation. Instructions are available on the ASN website and ASN eLearning Center.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

- 75 MOC points in the ABIM Maintenance of Certification (MOC) program; and
- 75 MOC points in the ABP Maintenance of Certification (MOC) program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABP MOC credit.

Statement from ABIM

This course has been developed as an original and independent educational offering based on the public ABIM examination blueprint and is not approved or endorsed by ABIM. In accordance with ABIM policy, no ABIM Board members have been involved in the development of this course. ASN cannot guarantee that attending this course will result in passing the ABIM examination.

Disclosure Statement

It is the policy of the American Society of Nephrology (ASN) that all individuals in a position to control the content of ASN's sponsored continuing education (CE) activities are expected to provide full disclosure for both themselves and their spouse/partner, and to indicate to the activity audience any financial or other relationship held by themselves or their spouse/partner 1) with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial service(s) discussed in an educational presentation; and 2) with any commercial supporter(s) of the activity. All responses should reflect activities within the previous 12 months. Furthermore, ASN requests all faculty to disclose at the time of their lecture any planned discussion of investigational and/or off-label use of pharmaceutical products or devices within their presentation. Participants should note that the use of products outside US Food and Drug Administration (FDA)-approved labeling should be considered experimental and are advised to consult current prescribing information for approval indications. The intent of this policy is not to prevent expert faculty with relevant relationship(s) with commercial interest(s) from involvement in CE, but rather to ensure that ASN CE activities promote quality and safety, are effective in improving medical practice, are based on valid content, and are independent of control from commercial interests and free of commercial bias. In addition, all faculty members were instructed to provide balanced, scientifically rigorous, and evidence-based presentations.

ASN requires all individuals in a position to control content for Kidney Week to complete disclosure forms. Responses are listed on the ASN website, in the meeting platform, and during sessions.

Certificates of Attendance for International Participants

Early Program participants can pick up printed Certificates of Attendance (not CME certificates for US participants) on Wednesday, October 23, at the programs. Annual Meeting participants can access online Certificates of Attendance (not CME certificates for US participants) from October 24, 2024, through January 31, 2025, at https://register.asn-online.org/2024/certificateofattendance/ or at Registration in Exhibit Hall C beginning October 25 at 1:00 p.m. Certificates are only available if you have picked up your meeting materials or printed your meeting badge onsite. If you have questions, please visit ASN Services in Lobby C of the convention center.

Confirm your Attendance and

Unlock More Kidney Week Features



To unlock session evaluations and claim CE credits and MOC points, you need to verify your attendance at ASN Kidney Week 2024.

Features:

- · Evaluate Kidney Week sessions
- Claim CE credit and/or MOC points
 (available from October 27 through December 18, 2024)
- Enter your Kidney Week On-Demand access code to view session recordings available in November



Scan the QR code onsite to verify your attendance and access these features!

Day-at-a-Glance **Wednesday, October 23**

Early Programs

Each Early Program requires separate registration from the Annual Meeting. Detailed schedules are available at each Early Program room.

7:00 a.m. Onsite Check-In and Continental Breakfast for all 7 Early Programs

Acid-Base, Fluid, and Electrolyte Balance Disorders 2024:

Challenging Issues for Clinicians Ballroom 20B/C

8:00 a.m. Onsite Sessions

6:00 p.m. Adjourn

Advances in Research Conference – Genome Engineering and

RNA-Based Therapeutics: From Bench to Potentially Curative Medicines.......Room 6A

8:00 a.m. Onsite Sessions

5:10 p.m. Adjourn

Between a Rock and a Hard Place: Practical Updates in Kidney Stone

8:00 a.m. Onsite Sessions 6:00 p.m. Adjourn

Critical Care Nephrology: 2024 Update Ballroom 20A

8:00 a.m. Onsite Sessions

5:45 p.m. Adjourn

Glomerular Diseases: 2024 Update Ballroom 20D

8:00 a.m. Onsite Sessions

6:00 p.m. Adjourn

8:00 a.m. Onsite Sessions 5:00 p.m. Adjourn

Point-of-Care Ultrasound in NephrologyRoom 1

ASN thanks FUJIFILM Sonosite, Inc. and Mindray North America for in-kind support.

8:00 a.m. Onsite Sessions

5:00 p.m. Adjourn



For current meeting information search for "ASN Kidney Week" in your app store or scan this QR code.





ASN Career Fair

Meet face-to-face with top employers looking to hire!

October 24–26, 2024 9:30 a.m. – 2:30 p.m.


Located in the Exhibit Hall



ASN invites you to take part in the ASN Career Fair. Connect with employers and find your next nephrology opportunity. It's FREE to attend!

Be on the lookout for the ASN Featured Employers Guide, including open positions from top employers delivered to your inbox after Kidney Week.

Take charge of your career! Upload or update your resume on the ASN Career Center.





Get your resume in front of employers hiring nephrology professionals who search the database.



Search for jobs that are posted right from your smartphone or tablet.



Be the first to get job alerts when a new position matching your criteria is available.



Gain resume writing tips and how to prepare for an interview.

Visit careers.asn-online.org to get started!

Visit the ASN Communities Lounge at ASN Kidney Week

Community discussions, networking, and collaboration. Exhibit Hall B, Booth 1529

Thursday, October 24

General & Clinical Nephrology Poster Tour	10:30 — 11:30 a.m.
Led by Edgar Lerma, MD, FASN, and Roger Rodby, MD, FASN.	
Overview of the Increasing Organ Transplant Access (IOTA) Model	11:30 a.m. — 12:30 p.m.

Overview of the Increasing Organ Transplant Access (IOTA) Model A synopsis and discussion of the new payment model with CMMI: what it means for your practice and role. Relevant for both general and transplant nephrologists. (Session 1)

Kidney Care Choices (KCC) Model Meeting 12:30 — 1:30 p.m.

An intimate discussion with CMMI about the KCC model, its future. and potential scenarios for your practice. (Session 1)

Phairify Demonstration 1:30 - 2:00 p.m.

Learn about the Physician Value Exchange and how to leverage this exclusive ASN member benefit. (Session 1)

Friday, October 25

Overview of the Increasing Organ Transplant Access (IOTA) Model 10:00 - 11:00 a.m. A synopsis and discussion of the new payment model with CMMI: what it means for your practice and role. Relevant for both general and transplant nephrologists. (Session 2)

New Features of Communities 11:00 a.m. — 12:30 p.m.

Overview of the new platform: intuitive widgets, personalized links, navigation tips, and more.

Phairify Demonstration 12:30 — 1:00 p.m.

Learn about the Physician Value Exchange and how to leverage this exclusive ASN member benefit. (Session 2)

Forum on Transplant Nephrology Training 1:00 - 2:00 p.m. ASN-AST effort to secure ACGME accreditation for transplant nephrology: briefing, questions and answers, and networking.

Led by Roy Bloom, MD, FASN, and Neeraj Singh, MD, FASN. Kidney Care Choices (KCC) Model Meeting 2:00 - 3:00 p.m.An intimate discussion with CMMI about the KCC model, its future,

Saturday, October 26

and potential scenarios for your practice. (Session 2)

Becoming a Community Leader 10:00 - 11:00 a.m. Engagement strategies, moderation, replies, and follow-through.

Communities Library 11:00 a.m. - 12:00 p.m.

Keyword searching, studies, reports, and credible research. Themed Communities 12:00 - 1:00 p.m.

Onco-nephrology, Kidney Transplantation, Women's Health and Research.

1:00 - 2:00 p.m. Mentor Match Program

Listen and partake in conversations.

Enrollment basics, search criteria, and building relationships.



Day-at-a-Glance **Thursday, October 24**

8:00 a.m. – 9:30 a.m.	
Opening Plenary: ASN President's Address, ASN President's Medal, State-of-the-Art Lecture	Hall D
9:30 a.m. – 2:30 p.m. (Exhibit Halls)	
Morning Break (9:30 a.m. – 10:00 a.m.)Exhib	
Scientific Exposition and Posters (9:30 a.m. – 2:30 p.m.)	
Poster Presentations by Authors (10:00 a.m. – 12:00 p.m.)	
Exhibitor Spotlights (10:00 a.m. – 1:45 p.m.)	ort Hall B
Please see pages 54-55 for spotlight schedule and topics.	
10:30 a.m. – 12:30 p.m.	
Basic/Clinical Science Sessions	
Extracellular Vesicles in Kidney Diseases: Tiny Packages with Big ImpactR	oom 6D
Renal and Extrarenal Sodium Handling in Blood Pressure Regulation,	
Including the Robert W. Schrier, MD, Endowed Lectureship	Room 5
Clinical Practice Sessions	
AKI across the Continuum: Tailoring AKI Management by Patient DemographyR	loom 6B
Cardio-Kidney Protection with SGLT2 Inhibition and Beyond - Honoring George Bakris Ballro	
Complement Activation in Glomerulonephritis: An Emerging Target in Multiple Diseases	
Green Nephrology: Innovations That Address the Carbon Footprint Conundrum in Dialysis	Room 8
Iron, Erythropoietin, and Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors in	
CKD and ESKDBallro	
Malignancy and Kidney Transplantation: Evolving Toward Personalized CareBallroor	
Peritoneal Dialysis Outside the United States: What Can We Learn? R	
What's New in Pediatric Kidney Transplantation?	loom 33
Translational Session	
Abnormalities in Calcium and Phosphorus in Malignancy:	
Mechanisms and Management Options	Room 7
Other Event	
Fellows-in-Training Bowl: Elimination Rounds Exhibit Hall B, Futures	Theater
12:45 p.m. – 1:45 p.m. Educational Symposia (Marriott Marquis San Diego Marina)	
Doors open at 12:30 p.m. Limited seating.	
Accepting the Complement: Understanding the Role of Complement and	
Its Targeted Therapies in IgA NephropathyMarriott Grand Bal	lroom 8
Hyperkalemia, CKD, and Heart Failure: Dietary and Medical Considerations Marriott Grand Bal	
Imaging and Multidisciplinary Care in ADPKDMarriott Grand Bal	
Mechanisms and Advances in ANCA-Associated VasculitisMarriott Grand Ballı	
1:00 p.m. – 2:00 p.m.	TI .
Top Trainee Posters - 1 Exhibit Hall B, Futures	Theater
2:00 p.m. – 4:00 p.m.	
Basic/Clinical Science Sessions	
A Dynamic Filtration Barrier: Insights from Experimental Models of Glomerular Diseases	oom 6A
Advances in Pathomechanisms of AKI	
Breakthroughs in Polycystic Kidney Disease ResearchBallro	

2:00 p.m. – 4:00 p.m.	
Basic/Clinical Science Sessions	
Model Organisms to Understand Kidney Development, Disease, and Homeostasi	s Room 2
Modern Insights into the Pathogenesis of Kidney Stone Disease	
Progress on Cellular Therapies for Tolerance and Pig-to-Human	
Xenotransplantation	Ballroom 20B/C
Resolving AKI Spatially and Temporally	
Updates in Chronic Interstitial Nephritis in Agricultural Communities	
What's New in Diuretics?	
Clinical Practice Sessions	
Case Studies in Onconephrology	Ballroom 20A
Kidney Connection to Heart Failure with Preserved Ejection Fraction	Room 5
Molecular Kidney Pathology Rounds	
Translational Sessions	
Challenges in the Management of Pediatric Glomerular Diseases	Poom 22
RNA-Centric View of Diabetic Kidney Disease in Translation	
NVA-CERTIC VIEW OF Diabetic Nulley Disease in Translation	
Kidney Transplantation in 2024: Change Isn't Coming, It's Here, Including the Christopher R. Blagg, MD, Endowed Lectureship in Kidney Diseases and Public	PolicyRoom 24
4,00 m	
4:00 p.m. – 4:30 p.m. Afternoon Break Fovers of Ballr	
4:00 p.m. – 4:30 p.m. Afternoon BreakFoyers of Ballro	
Afternoon Break	oom 20 and Room 6A
Afternoon Break	oom 20 and Room 6A agement Room 6A
Afternoon Break	oom 20 and Room 6A agement Room 6ARoom 6B
Afternoon Break	oom 20 and Room 6A agement Room 6A
Afternoon Break	agement Room 6A
Afternoon Break	agement Room 6A
Afternoon Break	agement Room 6A
Afternoon Break	agement Room 6A
Afternoon Break	agement Room 6A
Afternoon Break	agement Room 6A
Afternoon Break	agement Room 6A
Afternoon Break	agementRoom 6ARoom 6ARoom 6BBallroom 20DBallroom 20B/CRoom 7Room 6CRoom 2Room 24Room 6D
Afternoon Break	agementRoom 6ARoom 6BBallroom 20ABallroom 20B/CRoom 7Room 6CRoom 2Room 24Room 6DRoom 33
Afternoon Break	agementRoom 6ARoom 6ABallroom 20B/CRoom 7Room 6CRoom 24Room 6DRoom 33Room 4
Afternoon Break	agement Room 6A



6:00 p.m. – 7:00 p.m.

For current meeting information search for "ASN Kidney Week" in your app store or scan this QR code.



Thursday, October 24, 8:00 a.m. – 9:30 a.m.

	MaryHall D wided by an educational grant from Vera Therapeutics. ASN President's Address – Deidra Crews ASN President's Medal – Alonzo Mourning State-of-the-Art Lecture "Accelerating Health Care Innovation in Nephrology with Artificial Intelligence" – David Rhew
	Thursday, October 24, 10:30 a.m. – 12:30 p.m.
ASN thanks th	Vesicles in Kidney Diseases: Tiny Packages with Big Impact
Including the ASN gratefully several individ	trarenal Sodium Handling in Blood Pressure Regulation, Robert W. Schrier, MD, Endowed Lectureship
11:00 a.m. 11:30 a.m. 12:00 p.m.	Deciphering the Mechanism of Salt Transport in the Distal Convoluted Tubule – Eric Delpire Molecular Bases of Potassium and Sodium Balance, Electrolyte Disorders, and Hypertension: The Robert W. Schrier, MD, Endowed Lectureship – Paul Welling Dietary Sodium and BP in CKD: From Bench to Bedside – Dena Rifkin
	e Continuum: Tailoring AKI Management by Patient Demography

Thursday, October 24, 10:30 a.m. – 12:30 p.m.

	ey Protection with SGLT2 Inhibition and Beyond -
	eorge BakrisBallroom 20A he ASN Diabetic Kidney Disease Collaborative Task Force for assistance with this session.
	Daniel Gordin, Sylvia Rosas
10:30 a.m.	
10.30 a.m. 11:00 a.m.	Evidence for Use of SGLT2 Inhibitors and Translation to Practice – Rajiv Agarwal How Will the Incretin Data "FLOW" into Practice – Katherine Tuttle
11:30 a.m.	
11.30 a.m.	Nonsteroidal Mineralocorticoid Receptor Antagonists, Aldosterone
	Antagonism, and Kidney Protection: Making It "EASi" for the Kidneys –
12,00	Parminder Judge
12:00 p.m.	Integration of the American Heart Association Cardiovascular-Kidney- Metabolic Paradigm into Patient Care: Challenges and Opportunities –
	Chiadi Ndumele
	Chiadi Ndumele
Complement	t Activation in Glomerulonephritis:
An Emerging	Target in Multiple DiseasesRoom 6A
Support is pro	ovided by an educational grant from Travere Therapeutics, Inc.
Moderators:	lean Hou, Mariela Navarro Torres
10:30 a.m.	Complement Cascade and Its Inhibition – Richard Smith
11:00 a.m.	Complement as a Driver of Disease and Therapeutic Target in Immune
	Complex-Mediated Glomerulonephritis – Jonathan Barratt
11:30 a.m.	Role of Complement in the Pathogenesis and Treatment of Thrombotic
	Microangiopathy – Anuja Java
12:00 p.m.	Monoclonal Gammopathy of Renal Significance and Complement-Mediated
	Glomerular Injury: A Complicated Intersection – Nelson Leung
Green Nephi	rology: Innovations That Address the Carbon Footprint
Conundrum	in DialysisRoom 8
ASN thanks th	he ASN Health Care Justice Committee for assistance with this session.
Moderators: I	Brendan Bowman, Ankur Shah
10:30 a.m.	Assessing the Carbon Footprint of Dialysis: A Step Toward Environmentally
	Sustainable Kidney Care – Suzanne Watnick
11:00 a.m.	Addressing the Environmental Impact of Kidney Care – Amy Yau
11:30 a.m.	Sources of Variation in the Carbon Footprint of Different Dialysis Modalities –
	Anne Huml
12:00 p.m.	Addressing Kidney Health Equity and Climate Change – Mukta Baweja
Iron, Erythro	poietin, and Hypoxia-Inducible Factor-Prolyl
Hydroxylase	Inhibitors in CKD and ESKDBallroom 20D
Moderators: I	Monique Cho, Jay Wish
10:30 a.m.	Nonhematologic Effects of Iron Deficiency – Connie Rhee
11:00 a.m.	Which Iron Formulation? And When? – Diana Jalal
11:30 a.m.	Are All Erythropoietin-Stimulating Agents the Same? – Jodie Babitt
12:00 p.m.	Where Do Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors Belong in the
	Anemia Toolbox? – Steven Fishbane

Thursday, October 24, 10:30 a.m. – 12:30 p.m.

	and Kidney Transplantation: Evolving Toward Personalized Care Ballroom 206/C
	Christopher Blosser, Adam Bregman Patient Voice Commentator: Michael Young
10:30 a.m.	Transplant's Successes, but at a Cost – Michael Young
10:40 a.m.	Incidence, Risk Factors, and Mortality Risk of Cancer in Kidney Transplant
	Recipients – Angela Webster
11:05 a.m.	When Is It Safe to Transplant? Updated Recommendations for Skin and Solid-Organ Malignancy – Deirdre Sawinski
11:30 a.m.	Personalized Approach to Kidney Transplant Candidates with Hematologic Malignancy – Vinay Nair
11:55 a.m.	Novel Immunomodulatory Approaches to Patients with Advanced Cancer after Kidney Transplant – Naoka Murakami
12:20 p.m.	Questions and Answers
	alysis Outside the United States: What Can We Learn?Room 6C
Moderators: F	achel Fissell, Robert Quinn
10:30 a.m.	Assisted Peritoneal Dialysis: An Integral Component of Peritoneal Dialysis Delivery? – Edwina Brown
11:00 a.m.	Variety in Peritoneal Dialysis Fluids: Impact on Patient Outcomes – Andreas Vychytil
11:30 a.m.	Automated Peritoneal Dialysis or Continuous Ambulatory Peritoneal Dialysis: Variety Enables Flexibility and Person-Centered Delivery – Bourne Auguste
12:00 p.m.	PDOPPS Study: Center Size Matters, from Catheter Insertion to Time on Peritoneal Dialysis – Mark Lambie
	in Pediatric Kidney Transplantation?Room 33
	e Indian Society of Nephrology (ISN) and ISN Ambassador, Dr. Sanjeev Gulati.
	Rachel Engen, Sarah Kizilbash
10:30 a.m.	Noninvasive Tests for Monitoring Kidney Allograft Function and Rejection – Tom Blydt-Hansen
10:50 a.m.	Brief Updates on Management of Viral Infections after Kidney Transplant in Children – Vikas Dharnidharka
11:10 a.m.	Outcomes of Combined Kidney and Other Organ Transplants (Heart and Liver) in Children – Namrata Jain
11:30 a.m.	Improving Kidney Transplant Outcomes and Quality of Care – David Hooper
11:50 a.m.	Barriers to Deceased Donor Kidney Transplant in Emerging Economies – Sanjeev Gulati
12:10 p.m.	Questions and Answers
	s in Calcium and Phosphorus in Malignancy:
	and Management OptionsRoom 7
	/ictoria Gutgarts, Mitchell Rosner
10:30 a.m.	Malignancy-Associated Hypercalcemia: Prevalence, Impact, and Management – Shruti Gupta
11:00 a.m.	Humoral Hypercalcemia of Malignancy – Amanda Renaghan
11:30 a.m.	Hypophosphatemia in Cancer Therapy: Prevalence, Mechanisms, and
	Complications – Biruh Workeneh
12:00 p.m.	Bad to the Bone: Effect of Modern Cancer Therapeutics on Bone Health – Carrie Ye
	raining Bowl: Elimination RoundsExhibit Hall B, Futures Theater vided by IgANexus.
Support is pro	riaca by ignitional.

Note: Continuing education credits are not being offered for this activity.

Thursday, October 24, 12:45 p.m. - 1:45 p.m.

Educational Symposia (Marriott Marquis San Diego Marina)

Doors open at 12:30 p.m. Lunch is provided.

Limited seating; first-come, first-served to fully paid Annual Meeting participants.

Accepting the Complement: Understanding the Role of Complement

and Its Targeted Therapies in IgA Nephropathy...... Marriott Grand Ballroom 8

Support is provided by an educational grant from Novartis Pharmaceuticals Corporation.

12:45 p.m. Introduction – Sayna Norouzi (Moderator)

12:55 p.m. Understanding IgAN as a Complement-Mediated Disease – Felix Poppelaars

1:15 p.m. Targeting Complement in IgAN – Dana Rizk

1:35 p.m. **Questions and Answers**

Hyperkalemia, CKD, and Heart Failure:

Support is provided by an educational grant from AstraZeneca.

12:45 p.m. Introduction – Holly Kramer (Moderator)

12:55 p.m. Dietary Potassium: Effects on Serum Levels and Overall Health – Melanie Betz 1:15 p.m. Maximization of Renin Angiotensin Aldosterone (RAAS) Inhibition in CKD and

Heart Failure: Strategies for Hyperkalemia Management – Jamie Dwyer

1:35 p.m. **Questions and Answers**

Imaging and Multidisciplinary Care in ADPKD...... Marriott Grand Ballroom 4

Support is provided by an educational grant from Otsuka America Pharmaceutical, Inc.

12:45 p.m. **Introduction** – Terry Watnick (Moderator)

12:55 p.m. ADPKD Clinic: Optimizing Workforce Teamwork and Patient-Centered Care -

Michal Mrug

1:15 p.m. Radiographic Imaging to Refine Diagnosis and Prognosis in ADPKD -

Timothy Kline

1:35 p.m. Questions and Answers

Mechanisms and Advances in ANCA-Associated Vasculitis...... Marriott Grand Ballroom 13

This activity is supported by educational funding provided by Amgen.

12:45 p.m. Introduction – Ralph Kettritz (Moderator)

12:55 p.m. Treatment of ANCA-Associated Vasculitis – Duvuru Geetha

1:15 p.m. The Role of Endothelin in ANCA-Associated Vasculitis – Neeraj Dhaun

1:35 p.m. **Questions and Answers**

Wi-Fi Service

Free internet access is available in the convention center.

Search for the network "kidneyweek" (no password).

Supported by





Thursday, October 24, 2:00 p.m. – 4:00 p.m.

-	Itration Barrier: Insights from Experimental Models of Diseases
	vided by an educational grant from Travere Therapeutics, Inc.
	se Daehn, Tobias Huber
2:00 p.m.	Filtration Barrier Function in Zebrafish: Focus on Podocyte and Glomerular Endothelium – Janina Müller-Deile
2:30 p.m.	Slit Diaphragm Maintenance and Dynamics in Drosophila Nephrocytes – Tobias Hermle
3:00 p.m.	The Glomerular Mesangium: At the Center of It All – Jenny Nystrom
3:30 p.m.	Targeting the Mechanical Responses of the Podocyte Cytoskeleton – Di Feng
Advances in F	Pathomechanisms of AKIRoom 4
Moderators: A	mandeep Bajwa, Tomokazu Souma
2:00 p.m.	Targeting NAD Metabolism to Reduce AKI Severity – Amanda Clark
2:30 p.m.	Targeting Kinases to Limit AKI and Promote Repair – Navjot Pabla
3:00 p.m.	Building Resistance against AKI: Role for PAX Proteins – Jeffrey Beamish
3:30 p.m.	Fatty Acid Oxidation in AKI – Sunder Sims-Lucas
Breakthrough	ns in Polycystic Kidney Disease ResearchBallroom 20D
	eter Harris, Erum Hartung
2:00 p.m.	Fibrocystin and the PKHD1 Gene: Fragments and Functions – Feng Qian
2:30 p.m.	Visual Models to Characterize Mutations and Functions of the Polycystin Complex – Markus Delling
3:00 p.m.	Activation of Polycystin 1 as a G Protein-Coupled Receptor: Tethered Agonist and Synthetic Peptides – Robin Maser
3:30 p.m.	Downstream of Polycystin Loss in ADPKD: A Newly Defined Effector –
	Stefan Somlo
Dialysis Acces	ss Care: From Bench to BedsideRoom 6C
Moderators: Ji	e Cui, Roberto Vazquez-Padron
2:00 p.m.	Molecular Mechanisms of Vascular Access Failure – Timmy Lee
2:30 p.m.	Novel Therapies to Improve Arteriovenous Fistula Maturation – Joris Rotmans
3:00 p.m.	New Technologies to Create Arteriovenous Fistulas – Neghae Mawla
3:30 p.m.	Ten Years after the Hemodialysis Fistula Maturation Study – Laura Dember
	isms to Understand Kidney Development, Disease, and Homeostasis Room 2
Moderators: Z	haoxia Sun, Bradley Yoder
2:00 p.m.	Insights into Mammalian Kidney Development and Disease: Using the Mouse to Model Congenital Anomalies of the Kidneys and Urinary Tract – Leif Oxburgh
2:30 p.m.	Leveraging Caenorhabditis elegans to Elucidate Ciliary Dynamics in the Context of PKD – Maureen Barr
3:00 p.m.	Xenopus Models Yield New Insights into Renal Tubule Development – Soeren Lienkamp
3:30 p.m.	Model Organisms as Powerful Tools to Study Basement Membrane Biology and
5.56 p	Kidney Diseases – Rachel Lennon
Modern Insig	hts into the Pathogenesis of Kidney Stone DiseaseRoom 7
Moderators: Jo	ohn Lieske, Megan Prochaska
2:00 p.m.	Claudins and Kidney Stone Pathogenesis – Alan Yu
2:30 p.m.	Role of Inflammation in Kidney Stone Formation – Tarek El-Achkar
3:00 p.m.	Role of the Microbiome in Kidney Stone Formation – Lama Nazzal
3:30 p.m.	Genetics and Heritability of Kidney Stone Disease – John Sayer

Thursday, October 24, 2:00 p.m. – 4:00 p.m.

_	ellular Therapies for Tolerance and Pig-to-Human
	ntation Ballroom 20B/C
	ohn Gill, Jayme Locke
2:00 p.m.	Genetic Engineering and Immunosuppression in Pig-to-Human
	Xenotransplantation: Striking a Balance – Alfred Tector
2:30 p.m.	Near-Death Experience: Progress and Insights from Decedent Pig-to-Human
	Xenotransplantation – Robert Montgomery
3:00 p.m.	Chimerism and the Road to Transplant Tolerance: Where Do We Stand? –
	Joseph Leventhal
3:30 p.m.	Regulatory T Cells for Solid-Organ Transplantation: An Update on the ONE and
	TWO Studies – Fadi Issa
Resolving AKI	Spatially and TemporallyRoom 6B
ASN thanks the	e Japanese Society of Nephrology (JSN) and JSN Ambassador, Dr. Motoko Yanagita.
Moderators: Ke	elly Hyndman, Sushrut Waikar
2:00 p.m.	Spatial Transcriptomics to Define Injury Microenvironments – Michal Polonsky
2:30 p.m.	Intravital Microscopy to Track Kidney Injury – Ina Schiessl
3:00 p.m.	Controlling Neuroimmune Interactions in the Kidneys – Mark Okusa
3:30 p.m.	Tertiary Lymphoid Tissues and AKI Progression – Motoko Yanagita
	ronic Interstitial Nephritis in Agricultural Communities
	ophie Claudel, David (Daud) Sheikh-Hamad
2:00 p.m.	Clinical Manifestations and Prognosis of Chronic Interstitial Nephritis
	in Agricultural Communities: Similarities and Differences across the Globe –
	Marvin Gonzalez-Quiroz
2:30 p.m.	Environmental Exposures and Chronic Interstitial Nephritis in Agricultural
2.00	Communities across the Globe – Shuchi Anand
3:00 p.m.	Insights from Omics Approaches in Chronic Interstitial Nephritis in Agricultural
	Communities – Nishad Jayasundara
3:30 p.m.	Heat Stress, Volume Depletion, and AKI: Physiologic Studies of Water
	Regulation in Chronic Interstitial Nephritis in Agricultural Communities –
	Vivek Bhalla
What's New in	n Diuretics?Room 6D
	nna Gaddy, Ashita Tolwani
2:00 p.m.	Use of Acetazolamide in Volume Overload: Start at the Beginning –
	W.H. Wilson Tang
2:30 p.m.	More Salt: Hypertonic Saline for Augmenting Diuresis – Steven Coca
3:00 p.m.	Which One: Torsemide vs. Furosemide? – Lauren Cooper
3:30 p.m.	Which One: Chlorthalidone vs. Hydrochlorothiazide? – Areef Ishani
Case Studies i	n OnconephrologyBallroom 20A
	nruti Gupta, Kenar Jhaveri
2:00 p.m.	Case 1: AKI in Patients Treated with Several New Chemotherapy and
12	Immunotherapy Agents – Prakash Gudsoorkar
2:30 p.m.	Case 2: Proteinuria in Patients with Cancer – Mark Perazella
3:00 p.m.	Case 3: Estimating GFR in Patients with Cancer – Silvia Titan
3:30 p.m.	Case 4: New Electrolyte Derangements in Patients Treated for Cancer –
P	Biruh Workeneh

Thursday, October 24, 2:00 p.m. – 4:00 p.m.

Kidney Conn	ection to Heart Failure with Preserved Ejection Fraction Room 5
	Vendy McCallum, Marianne Verhaar
2:00 p.m.	Epidemiology and Mechanisms of HFpEF Phenotypes in Patients with Kidney Diseases – Rupal Mehta
2:30 p.m.	Interconnection between CKD, Obesity, and HFpEF: Pathophysiology and Management – Michael Hall
3:00 p.m.	Treatment of HFpEF in Patients with Kidney Diseases: Insights from Recent Clinical Trials – Hiddo Heerspink
3:30 p.m.	Physiology of Exercise Intolerance in HFpEF and Kidney Diseases – Senthil Selvaraj
Molecular Ki	dney Pathology RoundsRoom 1
	Debbie Gipson, Matt Sampson
2:00 p.m.	Experiences from a Real-World Nephrogenetic Clinic – Asaf Vivante
2:30 p.m.	Genetic Tubular Disorders Presenting as FSGS – Lihong Bu
3:00 p.m.	Collagenopathies in Glomerular Diseases: Beyond Alport Syndrome – Dominick Santoriello
3:30 p.m.	Implementing the Molecular Nephrology Board: The NEPTUNE Match Experience – Crystal Gadegbeku
Challenges in	the Management of Pediatric Glomerular DiseasesRoom 33
Moderators: L	ouise Oni, Madhura Pradhan
2:00 p.m.	Anticomplement Therapies in Typical and Atypical Hemolytic Uremic Syndrome i Children – Bradley Dixon
2:30 p.m.	Evaluating Kidney Disease Outcomes and Predictors of Outcomes in Pediatric-Onset ANCA-Associated Vasculitis – Kelly Brown
3:00 p.m.	Novel Mechanisms and Therapies for Pediatric IgA-Associated Vasculitis – Lili Liu
3:30 p.m.	Treatment Outcomes and Ongoing Pediatric Trials in Steroid-Resistant Nephrotic Syndrome – Chia-Shi Wang
RNA-Centric	View of Diabetic Kidney Disease in TranslationRoom 25
Moderators: N	Michael Eadon, Katalin Susztak
2:00 p.m.	Epigenetics and Epigenomics of Diabetic Kidney Disease – Rama Natarajan
2:30 p.m.	Role of MicroRNA in Diabetic Kidney Disease Progression – Eiichiro Satake
3:00 p.m.	Single-Cell and Spatial Modalities in Diabetic Kidney Disease Research – Benjamin Humphreys
3:30 p.m.	Potential for RNA-Based Therapeutics in Diabetic Kidney Disease – Akshay Desai
Christopher I	splantation in 2024: Change Isn't Coming, It's Here, Including the R. Blagg, MD, Endowed Lectureship in Kidney Diseases and Public Policy Room 24
	γ acknowledges the Northwest Kidney Centers and its contributors for support of the Blagg
Lectureship.	Citis Dellevide Dev Diegen
	Keith Bellovich, Roy Bloom
2:00 p.m.	Bye-Bye, Black Box: What Pre-Wait-Listing Data Collection Means for You and Your Patients – Rachel Patzer
2:30 p.m.	Navigating an Evolving Organ Procurement Landscape: The Christopher R. Blagg, MD, Endowed Lectureship in Kidney Diseases and Public Policy – Jesse Schold
3:00 p.m.	Utility, Equity, Transparency, or All of the Above in Organ Allocation? – Syed Husain
3:30 p.m.	What Happens When the Patient Receives a Kidney Transplant? – Vishnu Potluri

Thursday, October 24, 4:30 p.m. – 6:00 p.m.

	iated Vasculitis: Evidence and Uncertainties in
	and ManagementRoom 6A
	vided by an educational grant from Travere Therapeutics, Inc.
	Koyal Jain, Anushya Jeyabalan
4:30 p.m.	Predictive Tools and Prognostic Indicators in ANCA-Associated Glomerulonephritis – Silke Brix
4:50 p.m.	Pitfalls in Diagnosis of ANCA-Associated Vasculitis – Ingeborg Bajema
5:10 p.m.	New Therapeutic Targets and Therapies for ANCA-Associated
	Glomerulonephritis – A. Richard Kitching
5:30 p.m.	Indicators of Remission and Relapse in ANCA-Associated Vasculitis: Where Are We and What Are the Challenges? – Mark Little
Emerging Th	erapies for AKI: Bright HorizonsRoom 6B
Moderators: A	Ayse Akcan Arikan, Linda Awdishu
4:30 p.m.	What Went Wrong? The Graveyard of Pharmacotherapies for AKI – Peter Pickkers
4:50 p.m.	SGLT2 Inhibitors: Is There a Role for AKI Prevention? – Daniel Murphy
5:10 p.m.	Metformin for Sepsis-Associated AKI – Hernando Gómez Danies
5:30 p.m.	Kidney Regenerative Medicine: Stem Cells for AKI – LaTonya Hickson
	Patients Receiving DialysisBallroom 20A
	Cynthia Delgado, Jason Stubbs
4:30 p.m.	Protein Intake and Plant-Based Diets for Patients on Dialysis – Talat Alp Ikizler
4:50 p.m.	"Heart-Healthy" Diets for Patients on Dialysis: How Should We Counsel Our Patients? – Beth Shanaman
5:10 p.m.	Nutrition Considerations for Patients Receiving Peritoneal Dialysis – Angela Yee Moon Wang
5:30 p.m.	Modulating the Colon Microbiome by Diet in Patients on Dialysis – Keiichi Sumida
Transition to	Adulthood: Bringing Together Pediatric and Adult Nephrologists Ballroom 20D
Moderators: F	Rupesh Raina, Sai Kaumudi Saridey
4:30 p.m.	Challenges and Opportunities in Pediatric to Adult Transition of Care – Rebecca Levy
4:50 p.m.	Empowering Transplant Warriors in Their Journey to Adult Care: Bridging the Gap – Elaine Ku
5:10 p.m.	Transitioning to Adult CKD Care beyond the Kidneys: Growing Stronger Together – Alexander Kula
5:30 p.m.	Real-World Transition Models: Perspectives from a Clinician and a Caregiver – Maria Ferris
	ns and Kidney Transplantation Ballroom 20B/C
Moderators: [Daniel Brennan, Samira Farouk
4:30 p.m.	Novel Tools and Therapies in Surveillance and Management of BK Virus – Hans Hirsch
4:50 p.m.	Updates in New Diagnostics and Drugs in Cytomegalovirus Management – Deepali Kumar
5:10 p.m.	Reassessment of COVID-19 and Its Impact on Kidney Transplantation in 2024 – Emily Blumberg
5:30 p.m.	Advances in Understanding Viruses as a Barometer of Immunosuppression: Epstein-Barr Virus and Torque Teno Virus – John Friedewald

Thursday, October 24, 4:30 p.m. – 6:00 p.m.

ORAL ABSTRACT SESSIONS

Achieving More Equitable Kidney Care
AKI: New Frontiers in Prognostication and Management
Augmented Intelligence and Digital Health Advances
CKD: Novel Risk Factors and Consequences
CKD-MBD and Kidney Stones: Novel Insights
Diabetic Kidney Disease - Clinical: Novel Insights into Precision Medicine
Fluid, Electrolyte, and Acid-Base Disorders: Back to the Basics
Home Dialysis Hodgepodge: Novel Mechanisms, Solutions, Technologies, and Ideas Room 8 Moderators: Suma Prakash, Nikhil Shah
Hypertension and CVD: Research Advances Room 5 Moderators: Eman Gohar, Tanecia Mitchell
Non-Cystic Genetic Kidney Diseases: Disease Genes, Modifiers, and TherapiesRoom 23 Moderators: Rannar Airik, John Sayer
Podocytopathies and Membranous Nephropathy: Clinical Advances
Transplantation: Basic and Translational Advances



Please refer to the meeting mobile app or the ASN website for the list of abstracts and presenters.


Poster Sessions Thursday, October 24 | Exhibit Hall B

Poster Topics	Board #s
NIH/NIDDK and Informational Posters - 1	INFO01-INFO14
Augmented Intelligence for Prediction and Image Analysis	
AKI: Epidemiology, Risk Factors, and Prevention - 1	
AKI: Clinical, Outcomes, and Trials - Epidemiology and Pathophysiology	
PharmacologyPharmacology	
CKD-MBD: Clinical	
Hypertension and CVD: Basic Research Findings	
Hemodialysis, Hemodiafiltration, and Frequent Dialysis	
Hemodialysis and Frequent Dialysis - 1	
Sodium, Potassium, and Volume Disorders: Clinical	
Development, Organoids, Injury, and Regeneration	
Cystic Kidney Diseases: Clinical Assessment and Therapeutic Directions	
Genetic Kidney Diseases: Genotypes and Phenotypes in Cases	
Glomerular Diseases: Omics, Biomarkers, and Tools	
Membranous Nephropathy, FSGS, and Minimal Change Disease	
Lupus Nephritis: Clinical, Outcomes, and Therapeutics	
Glomerular Diseases: Case Reports - 1	
Transplantation: Clinical - 1	
Transplantation: Clinical - 2	
Race, Ethnicity, and Gender in Kidney Health and Care	
Anemia and Iron Metabolism	
Geriatric Nephrology: Innovations and Insights	919–954
Physical Activity and Lifestyle in Kidney Diseases	
CKD: Epidemiology, Risk Factors, and Prevention - 1	
CKD: Therapeutic Advances	
CKD: Mechanisms - 1	
COVID-19	1133–1164
Late-Breaking Clinical Trials	1165–TBD

Top Trainee Posters - 1

Thursday, October 24 1:00-2:00 p.m. **Exhibit Hall B, Futures Theater**

Note: Continuing education credits are not being offered for this activity.





You are invited to a hands-on review session of all the digital slides from the **Renal Biopsy: Clinical Correlations** session vignettes prior to Saturday, October 26 (2:00–4:00 p.m.), when the final diagnoses are discussed in depth and answers to the cases are distributed. Biopsy materials are available with renal pathologists onsite to direct your study of the cases and to provide individual instruction. There is no fee to visit the Pathology Room; however, space is limited and available on a first-come, first-served basis.

Thursday

October 24

9:30 a.m. — 4:30 p.m.

Friday

October 25

9:30 a.m. - 4:30 p.m.

ASN thanks the Renal Pathology Society for assistance with the Renal Biopsy session and the Digital Pathology Room.

The Digital Pathology Room is supported by





Cele's Champions: Cele Fogarty Travel Support Program for Patients

On behalf of the 850,000,000 people worldwide with kidney diseases, the Cele Fogarty Travel Support Program for Patients ("Cele's Champions") honors people living with kidney diseases or caring for an individual with kidney diseases by supporting their voice and advocacy.

Cecilia "Cele" Agnes Fogarty was a leading executive in event management and member services for decades, advancing the work of several major organizations, including ASN, in health care, medicine, science, and other areas. She was renowned for her ability to manage the most complex meeting logistics, anticipate challenges, and meet unexpected crises—large and small—with aplomb and sometimes magic.

Despite being diagnosed with kidney disease herself, Ms.

Fogarty continued to work towards "A world without kidney diseases," including the strenuous onsite meeting management, due to the flexibility of peritoneal dialysis, and the support of her care team. Her dedication and persistence parallel the courage and diligence to live well with a chronic disease.

Patient and family advocates who speak out for the people worldwide with kidney diseases.

To honor Ms. Fogarty, her commitment to mentorship, and her passion for accommodating all people regardless of the challenges they may face, ASN is committed to amplifying the patient voice throughout the organization and in its activities.

ASN is pleased to announce the 2024 "Cele's Champions"

- Dawn Bates
- Meradee Dransfield
- Dawn Edwards
- Valen Keefer
- Susan Reale

- Tangela Robinson
- David Rodriguez
- Chelsea Roman
- Melissa Tolzien
- Anne Walsh



Day-at-a-Glance Friday, October 25

6:45 a.m. – 7:45 a.m.	
Educational Symposia (Marriott Marquis San Diego Marina)	
Doors open at 6:30 a.m. Limited seating. Advances in Inflammation Mechanisms and Therapies to Reduce	
Atherosclerotic Cardiovascular Disease in Persons with Kidney Dis	eases Marriott Grand Ballroom 5
Ushering Renal Denervation from Trials into the Real World	
8:00 a.m. – 9:30 a.m.	
Plenary: Robert G. Narins Award, John P. Peters Award, Donald W. Se	
Young Investigator Award and Address, State-of-the-Art Lecture.	Hall D
9:30 a.m. – 2:30 p.m. (Exhibit Halls)	
Morning Break (9:30 a.m. – 10:00 a.m.)	
Scientific Exposition and Posters (9:30 a.m. – 2:30 p.m.)	
Poster Presentations by Authors (10:00 a.m. – 12:00 p.m.) Exhibitor Spotlights (10:00 a.m. – 1:45 p.m.)	
Please see pages 54-55 for spotlight schedule and topics.	EXTIDIT HAII B
10:30 a.m. – 12:30 p.m.	
Clinical Practice Sessions	
Arrythmias in Patients with Kidney Diseases: Finding the Right Rhyth	m Room 5
Breaking Down Barriers to Transplantation: Management of Older Ad	dults and
Individuals with Obesity	Ballroom 20B/C
Osteoporosis in CKD: Updates in Pathogenesis and Management	
Person-Centered Decision-Making for Older People Choosing Dialys	
Sickle Cell Disease and the Kidneys: Emerging Concepts and Gene Th	
Therapeutic Decisions in Glomerular Diseases: Updating the Algorith	
Unraveling the Secrets of Complicated Extracorporeal Circuits: Maze	to MasteryRoom 6B
Translational Sessions	145
Heterogeneity of Diabetic Kidney Disease, Including the Garabed Ek	-
Endowed Lectureship Neonatal and Pediatric AKI: Advances in Prediction and Treatment	
	R00III 33
Oral Abstract Session High-Impact Clinical Trials - 1	Hall D
	Ilali D
Other Event Fellows-in-Training Bowl: Semi-Finals and Finals	Evhibit Hall R. Futures Theater
	Exhibit Hall b, Futures Hieater
12:45 p.m. – 1:45 p.m. Educational Symposia (Marriott Marquis San Diego Marina)	
Doors open at 12:30 p.m. Limited seating.	
Expanding Therapeutic Landscape in Lupus Nephritis:	
Utilization of B Cell Targeted Therapy	Marriott Grand Ballroom 13
Targeting the Pathophysiology of Hyperphosphatemia in ESKD:	
From Physiology to Clinical Innovation	Marriott Grand Ballroom 5
The Role of Hemodiafiltration in the Management of	
Dialysis-Dependent Chronic Kidney Failure	
Treatment of Anemia of CKD: What Is the Role of Hypoxia-Inducible	
Prolyl Hydroxylase Inhibitors?	Marriott Grand Ballroom 8
1:00 p.m. – 2:00 p.m.	
Top Trainee Posters - 2	Exhibit Hall B, Futures Theater

2:00 p.m. – 4:00 p.m.	
Basic/Clinical Science Sessions	
Best of ASN Journals: JASN, CJASN, and Kidney360	
Interorgan Cross-Talk: Kidney Injury and More	
Large Genomic and Multi-Omic Datasets to Inform Kidney Biology and Diseases	Room 2
Lymphatics and Immune Cell Activation in Cardiorenal Disease	
Opposing Demands in Kidney Injury: How to Adapt	
Podocyte Mechanosignaling in Health and Disease: Putting Their Feet Down	
Understanding Potassium Stress: Sensors, Signals, and Tubular Injury -	R00111 23
Honoring Charles Wingo	Room 8
Clinical Practice Sessions	
Case Studies in Glomerular Diseases 2024	Room 6A
Revisiting "Middle Molecules": Blast from the Past	
Salt, Water, Acid, Stone: Mastering Challenging Cases of Electrolyte and Acid-Base	
Disorders, Including the Burton D. Rose, MD, Endowed Lectureship	Room 6D
Why Aren't We Sharing More Declined Kidney Offers with Wait-Listed Patients?	
Including the Celeste Castillo Lee Endowed Lectureship	Room 23
Translational Sessions	
A to X Nephrology Hot Topics: Autoantibodies, Clazakizumab, Semaglutide (FLOW),	
and Xenotransplantation	Ballroom 20A
Advances in Pediatric CKD and ESKD	
APOL1-Mediated Kidney Disease: Year in Review, Including the Michelle P. Winn, MD	,
Endowed Lectureship	
Vascular Calcification and CKD: Is It Time to Start Treating?	Room 7
Special Session	
Supporting a Diverse Workforce in Nephrology	Room 24
Supporting a Diverse Workforce in Nephrology	Room 24
Supporting a Diverse Workforce in Nephrology	
Supporting a Diverse Workforce in Nephrology	
4:00 p.m. – 4:30 p.m. Afternoon Break	
4:00 p.m. – 4:30 p.m. Afternoon Break	20 and Room 6A
4:00 p.m. – 4:30 p.m. Afternoon Break	20 and Room 6A
4:00 p.m. – 4:30 p.m. Afternoon Break	20 and Room 6A
4:00 p.m. – 4:30 p.m. Afternoon Break	20 and Room 6A
4:00 p.m. – 4:30 p.m. Afternoon Break	20 and Room 6ABallroom 20DRoom 6B
4:00 p.m. – 4:30 p.m. Afternoon Break	20 and Room 6ABallroom 20DRoom 6B tsRoom 6ABallroom 20B/C
4:00 p.m. – 4:30 p.m. Afternoon Break	20 and Room 6ABallroom 20DRoom 6B tsRoom 6ABallroom 20B/C
4:00 p.m. – 4:30 p.m. Afternoon Break	20 and Room 6ABallroom 20DRoom 6B tsRoom 6ABallroom 20B/CBallroom 20A
4:00 p.m. – 4:30 p.m. Afternoon Break	20 and Room 6ABallroom 20DRoom 6B tsRoom 6ABallroom 20B/CBallroom 20A
4:00 p.m. – 4:30 p.m. Afternoon Break	20 and Room 6ABallroom 20DRoom 6B tsRoom 6ABallroom 20B/CBallroom 20ABallroom 20A
4:00 p.m. – 4:30 p.m. Afternoon Break	20 and Room 6ABallroom 20DRoom 6B tsRoom 6ABallroom 20B/CBallroom 20ABallroom 20ARoom 25Room 23Room 8
4:00 p.m. – 4:30 p.m. Afternoon Break	20 and Room 6ABallroom 20DRoom 6B tsRoom 6ABallroom 20B/CBallroom 20ARoom 25Room 23Room 8Room 4
4:00 p.m. – 4:30 p.m. Afternoon Break	20 and Room 6ABallroom 20DRoom 6B tsRoom 6ABallroom 20B/CBallroom 20ARoom 25Room 23Room 8Room 4Room 1
4:00 p.m. – 4:30 p.m. Afternoon Break	20 and Room 6ABallroom 20DRoom 6B tsRoom 6ABallroom 20B/CBallroom 20ARoom 25Room 23Room 8Room 4Room 1Room 5
4:00 p.m. – 4:30 p.m. Afternoon Break	20 and Room 6ABallroom 20DRoom 6B tsRoom 6ABallroom 20B/CBallroom 20ARoom 25Room 23Room 8Room 4Room 1Room 5Room 6D
4:00 p.m. – 4:30 p.m. Afternoon Break	20 and Room 6ABallroom 20DRoom 6B tsRoom 6ABallroom 20B/CBallroom 20ARoom 25Room 23Room 8Room 4Room 1Room 5Room 6DRoom 7
4:00 p.m. – 4:30 p.m. Afternoon Break	20 and Room 6ABallroom 20DRoom 6B tsRoom 6ABallroom 20B/CBallroom 20ARoom 25Room 23Room 8Room 4Room 1Room 5Room 6DRoom 7Room 33

Friday, October 25, 6:45 a.m. – 7:45 a.m.

Educational Symposia (Marriott Marquis San Diego Marina)

Doors open at 6:30 a.m. Breakfast is provided.
Limited seating; first-come, first-served to fully paid Annual Meeting participants.

5

8

Reduce Athe	Inflammation Mechanisms and Therapies to erosclerotic Cardiovascular Disease in Persons with eases
Support is pro	ovided by an educational grant from Novo Nordisk.
6:45 a.m.	Introduction – Michel Chonchol (Moderator)
6:55 a.m.	Inflammation as a Mechanism for ASCVD in Kidney Diseases – Steven Crowley
7:15 a.m.	Advances in Therapies to Target Inflammation to Reduce Atherosclerosis in
	Kidney Diseases – Laura Dember
7:35 a.m.	Questions and Answers
Ushering Re	nal Denervation from Trials into the Real World Marriott Grand Ballroom
Support is pro	ovided by an educational grant from Medtronic.
6:45 a.m.	Introduction – Tara Chang (Moderator)
6:55 a.m.	Long-Term Effectiveness and Patient Perspectives of Renal Denervation:
	Is It Ready for the Real World? – Swapnil Hiremath
7:15 a.m.	Developing a Team-Based Approach to Identifying, Screening, and Following
	Patients for Renal Denervation – Karen Griffin

Friday, October 25, 8:00 a.m. – 9:30 a.m.

The Donald W	/. Seldin Young Investigator Award is cosponsored by ASN and the American Heart
Association C	ouncil on the Kidney in Cardiovascular Disease.
Support for th	is session is provided by an educational grant from Vera Therapeutics.
Note: Continu	ing education credits are not being offered for this activity.
8:00 a.m.	Robert G. Narins Award – Scott Gilbert
8:15 a.m.	John P. Peters Award – Susan Quaggin
8:30 a.m.	ASN-AHA Donald W. Seldin Young Investigator Award and Address
	"Innovations in Clinical Trial Design and Conduct for New Therapeutic
	Approaches in CKD" – Hiddo Heerspink
9:00 a.m.	State-of-the-Art Lecture "From Reading the Genome for Risk to Rewriting It for
	Cardiovascular Health" – Sekar Kathiresan

7:35 a.m.

Questions and Answers

Friday, October 25, 10:30 a.m. – 12:30 p.m.

	Patients with Kidney Diseases: Finding the Right Rhythm
11:00 a.m.	Atrial Fibrillation in Kidney Diseases: Different Population, Different Disease – Nisha Bansal
11:30 a.m.	Anticoagulation to Treat Atrial Fibrillation in Patients Receiving Dialysis: Pro – Wolfgang Winkelmayer
12:00 p.m.	Anticoagulation to Treat Atrial Fibrillation in Patients Receiving Dialysis: Con – Crystal Gadegbeku
Breaking Dov	vn Barriers to Transplantation: Management of Older Adults and
	ith Obesity Ballroom 20B/C
Moderators: N	Nohammed Javeed Ansari, Neeraj Singh
10:30 a.m.	Surgical Approaches to Kidney Transplant Candidates with Obesity – Enrico Benedetti
11:00 a.m.	Long-Term Outcomes of Kidney Transplant Recipients with Obesity – Sumit Mohan
11:30 a.m.	Redefining Risk in Older Adults and Beyond: Importance of Frailty in Kidney
	Transplantation – Dorry Segev
12:00 p.m.	Evaluation, Monitoring, and Interventions for Older and Frail Kidney Transplant Candidates – Krista Lentine
	in CKD: Updates in Pathogenesis and ManagementRoom 7
Moderators: N	1atthew Allen, Aline Martin
10:30 a.m.	Diagnosis of Osteoporosis in CKD – Rosa Moyses
11:00 a.m.	Mechanistic View of the Therapeutic Landscape of Osteoporosis in CKD – Marie-Helene Lafage-Proust
11:30 a.m.	When to Intervene? Management of Osteoporosis in CKD – John Cunningham
12:00 p.m.	Updates in Management of Transplant Osteoporosis – Pascale Khairallah
	red Decision-Making for Older People Choosing DialysisRoom 6C
Moderators: P	atrick Gee, Marcello Tonelli
10:30 a.m.	Where Should I Have Dialysis: Home or In-Center? – Matthew Oliver
11:00 a.m.	Can I Have a Kidney Transplant? – Michelle Willicombe
11:30 a.m.	Choosing Conservative Care Is Not Just Saying "No" to Dialysis – Sara Davison
12:00 p.m.	"I Want to Live to See My Grandchildren Grow Up": Enabling Realistic
	Expectations – Ann O'Hare
	sease and the Kidneys: Emerging Concepts and Gene Therapies Ballroom 20D
	anya Johns, Anthony Muiru
10:30 a.m.	Prevention and Management of Sickle Cell Nephropathy – Bessie Young
11:00 a.m.	Emerging Concepts in Sickle Cell Trait and the Kidneys – Kabir Olaniran
11:30 a.m.	Gene Therapies for Sickle Cell Disease – Alexis Thompson
12:00 p.m.	What Is on the Therapeutic Horizon for Sickle Cell Disease and Sickle Cell Trait? – Santosh Saraf

Friday, October 25, 10:30 a.m. – 12:30 p.m.

	Decisions in Glomerular Diseases: Updating the AlgorithmsRoom 6A
	ided by an educational grant from Travere Therapeutics, Inc.
	nnette Bruchfeld, Ali Mehdi
10:30 a.m.	Management of Acute ANCA-Associated Glomerulonephritis: Evidence and Uncertainties – Duvuru Geetha
11:00 a.m.	Approach to Maintenance Therapy in Lupus Nephritis – Samir Parikh
11:30 a.m.	Use of SGLT2 Inhibitors, Endothelin Receptor Antagonists, and Targeted-
	Release Formulation Budesonide in IgAN – Pietro Canetta
12:00 p.m.	Treatment of Minimal Change Disease: Beyond Corticosteroids – Ladan Zand
12.00 p.m.	Treatment of Minimal change bisease, beyond condesseroids
Unraveling th	e Secrets of Complicated Extracorporeal Circuits: Maze to MasteryRoom 6B
Moderators: Pr	ramod Guru, Anitha Vijayan
10:30 a.m.	Merging Lifelines: Extracorporeal Membrane Oxygenation and Dialysis – Ankit Sakhuja
11:00 a.m.	Selective Cytopheretic Device for Inflammation Intervention – Lenar Yessayan
11:30 a.m.	Filtering for the Future: Blood Purification Technologies – Ashita Tolwani
12:00 p.m.	Mixing and Matching Technology: System- and Team-Level Perspective –
,	Rajit Basu, Theresa Mottes
Uatava nanaitr	y of Diabetic Kidney Disease,
	Garabed Eknoyan, MD, Endowed LectureshipBallroom 20A
	acknowledges Wadi N. Suki, MD, for support of the Eknoyan Endowed Lectureship.
	aipul Md Dom, Jonathan Rosen
10:30 a.m.	Disparities between Men and Women in the Course of Diabetic Kidney Disease: The Garabed Eknoyan, MD, Endowed Lectureship – Adeera Levin
11:00 a.m.	Diabetic Kidney Disease Differing by Race or Ethnicity: Insights from Pacific Islanders and Other Subpopulations – Marcus Pezzolesi
11:30 a.m.	Diabetic Kidney Disease by Diabetes Type – Meda Pavkov
12:00 p.m.	Causes of Nondiabetic Kidney Diseases in Diabetes – Amy Mottl
Noonatal and	Podiatric AVI: Advances in Prediction and Treatment Poem 22
Neonatal and Pediatric AKI: Advances in Prediction and Treatment	
10:30 a.m.	What's New for AKI Prediction in Neonates and Children: How to Implement
10.30 a.111.	Advances in Your Own Center – Prasad Devarajan
11:00 a.m.	Precision Medicine Approaches to Identifying Children in the Intensive Care
11.00 a.III.	Unit with Risk for Future AKI and CKD – David Selewski
11.20	
11:30 a.m.	Artificial Intelligence Approaches to Increasing Recognition and Follow-Up of Pediatric AKI – Michelle Starr
12:00 p.m.	Personalized Medicine Approaches in Choosing among New Neonatal Kidney
	Replacement Modalities – Shina Menon
High-Impact (Clinical Trials - 1Hall D
Please check the meeting mobile app or the ASN website for the list of abstracts and presenters.	
I LEUSE CHECK III	is meeting modile upp of the ASM website for the list of abstracts and presenters.
	aining Bowl: Semi-Finals and FinalsExhibit Hall B, Futures Theater
	ided by IgANexus.
Note: Continui	ng education credits are not being offered for this activity.

Friday, October 25, 12:45 p.m. – 1:45 p.m.

Educational Symposia (Marriott Marquis San Diego Marina)

Doors open at 12:30 p.m. Lunch is provided. Limited seating; first-come, first-served to fully paid Annual Meeting participants.

Utilization of B Cell Targeted Therapy
 12:45 p.m. Introduction – Isabelle Ayoub (Moderator) 12:55 p.m. Pathogenesis of Lupus Nephritis: Focus on B Cell Tolerance – Hans Anders
12:55 p.m. Pathogenesis of Lupus Nephritis: Focus on B Cell Tolerance – Hans Anders
1:15 p.m. Treatment of Lupus Nephritis: Focus on B Cell Targeting Therapies –
Dawn Caster
1:35 p.m. Questions and Answers
Targeting the Pathophysiology of Hyperphosphatemia in ESKD:
From Physiology to Clinical Innovation Marriott Grand Ballroom
Support is provided by an educational grant from Ardelyx, Inc.
12:45 p.m. Introduction – Jaime Uribarri (Moderator)
12:55 p.m. Mechanisms of Hyperphosphatemia in ESKD: The Interplay of Physiology, Diet,
and Pharmacotherapy – Julia Scialla
1:15 p.m. Hyperphosphatemia in ESKD: Is It Time for a Therapeutic Paradigm Shift? –
Michal Melamed
1:35 p.m. Questions and Answers
The Role of Hemodiafiltration in the Management of
Dialysis-Dependent Chronic Kidney Failure Marriott Grand Ballroom
Support is provided by an educational grant from Fresenius Medical Care Renal Therapies Group LLC.
12:45 p.m. Introduction – Philip Li (Moderator)
12:55 p.m. The Technological Aspects of HDF – Bernard Canaud
1:15 p.m. Effect of HDF on the Quality of Life and Mortality of Patients: A Review of the
Randomized Clinical Trials – Muriel Grooteman
1:35 p.m. Questions and Answers
Treatment of Anemia of CKD: What Is the Role of Hypoxia-Inducible Factor
Prolyl Hydroxylase Inhibitors? Marriott Grand Ballroom
Support is provided by an educational grant from Akebia Therapeutics, Inc.
12:45 p.m. Introduction – Wendy St. Peter (Moderator)
12:55 p.m. The Science behind HIF-PHI Development: From Bench to Clinical Trials – Daniel Coyne
1:15 p.m. Incorporating HIF-PHIs into Clinical Practice – Jay Wish
1:35 p.m. Questions and Answers

Friday, October 25, 2:00 p.m. – 4:00 p.m.

Best of ASN J	ournals: JASN, CJASN, and Kidney360Ballroom 20B/C
	e ASN family of journals for assistance with this session.
	rin Barreto, Tarek El-Achkar
2:00 p.m.	AKI and Intensive Care Unit Nephrology – Michael Heung
2:30 p.m.	Glomerular Diseases – Shuta Ishibe
3:00 p.m.	Therapeutic Advances in CKD – Magdalena Madero
3:30 p.m.	Care of Patients Undergoing Long-Term Dialysis – Mariana Murea
Interorgan Cr	oss-Talk: Kidney Injury and MoreRoom 6B
	e Korean Society of Nephrology (KSN) and KSN Ambassador, Dr. Sang-Kyung Jo.
Moderators: Jo	odie Babitt, Zheng Dong
2:00 p.m.	Kidney-Lung Cross-Talk in AKI – Andreas Herrlich
2:30 p.m.	Kidney-Gut Cross-Talk in AKI – Sang-Kyung Jo
3:00 p.m.	Interorgan Cross-Talk at the Bench and Bedside – Kent Doi
3:30 p.m.	Cardiac Remodeling in Kidney Diseases – TBD
	•
Large Genom	ic and Multi-Omic Datasets to Inform Kidney Biology and Diseases Room 2
Moderators: A	lexander Chang, Albertien van Eerde
2:00 p.m.	Use of a Clinical Exome Sequencing Database to Identify New Kidney Disease
·	Genes – Jennifer Posey
2:30 p.m.	Genetic Studies of Paired Metabolomes Reveal Processes at the Interface of
·	Plasma and Urine – Anna Kottgen
3:00 p.m.	Proteomics Integrated with Genomics in 138,000 Individuals Identify Putative
·	Novel Drug Targets for CKD – João Fadista
3:30 p.m.	Polygenic Risk Alters the Penetrance of Monogenic Kidney Diseases –
	Krzysztof Kiryluk
Lymphatics a	nd Immune Cell Activation in Cardiorenal Disease Room 5
Moderators: N	lirupama Ramkumar, Clintoria Williams
2:00 p.m.	Lymphatics and Gut-Kidney Cross-Talk – Valentina Kon
2:30 p.m.	Lymphatics and Kidney Diseases and Cardiorenal Syndrome – Anupam Agarwal
3:00 p.m.	Kidney Lymphatics in Heart Failure – Marat Fudim
3:30 p.m.	Lymphatics and the Renin-Angiotensin System – Brett Mitchell
·	
Opposing De	mands in Kidney Injury: How to AdaptRoom 4
Moderators: N	Nichael Balzer, Sian Piret
2:00 p.m.	Caloric Restriction, Aging, and Kidney Injury – Martin Späth
2:30 p.m.	Learning from Host and Microbe Interactions: Controlling Collateral Damage –
	Miguel Soares
3:00 p.m.	Antiviral Response and Kidney Injury – Deborah Lenschow
3:30 p.m.	What Is Compensatory Kidney Hypertrophy? – Hiroaki Kikuchi

Friday, October 25, 2:00 p.m. – 4:00 p.m.

Support is prov	chanosignaling in Health and Disease: Putting Their Feet Down
2:00 p.m.	Stressed Out: Unraveling the Mechanisms of Podocyte Mechanosignaling – Nicole Endlich
2:30 p.m.	Holding Tight: Measurement of Podocyte Force Development Using Elastic Resonator Interference Stress Microscopy – Malte Gather
3:00 p.m.	Standing in the GAP: Exploring the Role of ARHGAP29 in YAP-Mediated Mechanosignaling in Podocytes – Christoph Schell
3:30 p.m.	Standing Firm: Considering the Therapeutic Potential of Targeting Podocyte Mechanosignaling – Markus Rinschen
	er Differences in the Pathogenesis and Complications of CKDRoom 25
	e ASN Diabetic Kidney Disease Collaborative Task Force for assistance with this session.
	eisa Mathis, Jennifer Pluznick
2:00 p.m.	Sex, Gender, and CKD – Sofia Ahmed
2:30 p.m.	Sex and Gender Differences in CVD – Heddwen Brooks
3:00 p.m.	Sex Differences in Kidney Hemodynamics and Autoregulation – Aaron Polichnowski
3:30 p.m.	Sex Differences in Chronic Salt-Sensitive Hypertension and Kidney Damage – Justine Abais-Battad
	g Potassium Stress: Sensors, Signals, and Tubular Injury -
	rles WingoRoom 8
	ama Al-Qusairi, Michelle Gumz
2:00 p.m.	Kir4.2 and Potassium-Dependent Proximal Tubule Injury – Andrew Terker
2:30 p.m.	Role of WNK Body Condensates in Potassium Homeostasis – Cary Boyd-Shiwarski
3:00 p.m.	mTORC2 and the Rapid Kaliuretic Response – David Pearce
3:30 p.m.	Contribution of the Renal H+/K+ ATPases to Potassium Homeostasis: In Memory of Charles Wingo – Luciana Morla
Case Studies i	n Glomerular Diseases 2024Room 6A
	ided by an educational grant from Travere Therapeutics, Inc.
	eal Herlitz, Brad Rovin
2:00 p.m.	Case 1: Glomerulonephritis in Older Adults – Shikha Wadhwani
2:30 p.m.	Case 2: Glomerulonephritis and Genetic Testing – Ali Poyan-Mehr
3:00 p.m.	Case 3: Glomerulonephritis in Pregnant Patients – Salem Almaani
3:30 p.m.	Case 4: Glomerulonephritis in Children – Keisha Gibson
Revisiting "M	iddle Molecules": Blast from the PastRoom 6C
	lichael Allon, Sahir Kalim
2:00 p.m.	From Middle Molecules to Large Solutes: A History – Tammy Sirich
2:30 p.m.	Removal of Large Solutes by Hemodiafiltration vs. Hemodialysis – John Daugirdas
3:00 p.m.	How Well Does Peritoneal Dialysis Remove Large Solutes? – Simon Davies
3:30 p.m.	Clinical Effects of Increasing Large Solute Removal – Tariq Shafi
5.50 p.111.	Tany Shan

Friday, October 25, 2:00 p.m. – 4:00 p.m.

Salt Water A	Acid, Stone: Mastering Challenging Cases of Electrolyte and
	sorders, Including the Burton D. Rose, MD, Endowed LectureshipRoom 6D
	acknowledges Wolters Kluwer (publisher of UpToDate), the Beth Israel Deaconess
	r Department of Medicine Foundation, the Rose Family, and several of Dr. Rose's
	supporting this lectureship.
-	taci Leisman, Helbert Rondon Berrios
2:00 p.m.	Water Disorders: The Burton D. Rose, MD, Endowed Lectureship – Roger Rodby
2:30 p.m.	Potassium Disorders – Biff Palmer
3:00 p.m.	Acid-Base Disorders – Michael Emmett
3:30 p.m.	Divalent Cation Disorders – Laura Maursetter
Why Aren't V	Ve Sharing More Declined Kidney Offers with Wait-Listed Patients?
	Celeste Castillo Lee Endowed LectureshipRoom 23
	acknowledges Travere Therapeutics and several of Celeste's family members, friends, and
	support of the Celeste Castillo Lee Endowed Lectureship.
	uzanne Watnick, David White
2:00 p.m.	Catalyzing Advances in the Kidney Transplant Candidate Selection Process –
2,20 = ==	Matthew Cooper There is No. Delector Patients Should Be Bort of the Salection Conference.
2:30 p.m.	There is No Debate: Patients Should Be Part of the Selection Conference:
2.00	The Celeste Castillo Lee Endowed Lectureship – Nichole Jefferson
3:00 p.m.	Wait-List Management and Organ Acceptance Outside the United States – Joyce Popoola
3:30 p.m.	Using Shared Decision-Making to Reduce the Kidney Transplant Wait-List –
	Syed Husain
	ology Hot Topics: Autoantibodies, Clazakizumab,
	(FLOW), and XenotransplantationBallroom 20A
	usan Quaggin, Wolfgang Winkelmayer
2:00 p.m.	Autoantibodies Targeting Nephrin in Podocytopathies – Tobias Huber
2:30 p.m.	IL-6 Inhibition with Clazakizumab in Patients Receiving Maintenance Dialysis – Glenn Chertow
3:00 p.m.	Effects of Semaglutide on CKD in Patients with Type 2 Diabetes (FLOW) – Katherine Tuttle
3:30 p.m.	Genetically Edited Pig-to-Human Kidney Transplantation – Leonardo Riella
Advances in F	Pediatric CKD and ESKDRoom 33
Moderators: E	laine Ku, Sarah Swartz
2:00 p.m.	How Can Metabolomics and Lipidomics Predict Outcomes of Pediatric CKD? –
	Michelle Denburg
2:30 p.m.	Metabolic Bone Disease in Pediatric CKD: What's New? – Isidro Salusky
3:00 p.m.	Therapies for Neonates with Severe Early-Onset ESKD: Outcomes of the RAFT
	Trials – Meredith Atkinson
3:30 p.m.	Adolescent Patients on Dialysis: How to Effectively Transition to Adult
	Nephrology – Raj Munshi

Friday, October 25, 2:00 p.m. – 4:00 p.m.

	ated Kidney Disease: Year in Review,
	e Michelle P. Winn, MD, Endowed LectureshipBallroom 20D
	v acknowledges Duke University School of Medicine, the school's Division of Nephrology,
	dividuals for support of the Winn Endowed Lectureship.
	Opeyemi Olabisi, Andreia Watanabe
2:00 p.m.	APOL1-Mediated Kidney Disease: Variably Proteinuric, Yet Invariably
2.22	Progressive: The Michelle P. Winn, MD, Endowed Lectureship – Kirk Campbell
2:30 p.m.	Genetic and Environmental Modifiers of APOL1-Mediated Kidney Disease:
2.00	All in the Genes? – Simone Sanna-Cherchi
3:00 p.m.	Can We Eat Our Way out of APOL1-Mediated Kidney Disease? Impact of Nutrition on Disease Progression – Titilayo Ilori
3:30 p.m.	New Targets for Pharmacologic Therapy in APOL1-Mediated Kidney Disease – David Friedman
	cification and CKD: Is It Time to Start Treating?Room 7
	Cecilia Giachelli, Myles Wolf
2:00 p.m.	Molecular Approach to Understand Effects of Phosphate on Vascular Calcification – Mandy Turner
2:30 p.m.	New Strategies to Control Hyperphosphatemia and Vascular Calcification in CKD – Jason Stubbs
3:00 p.m.	New Strategies to Evaluate Calcium Balance in CKD – Rukshana Shroff
3:30 p.m.	Clinical Trials to Prevent Vascular Calcification Progression: Should We Start to Treat? – Smeeta Sinha
	Diverse Workforce in NephrologyRoom 24
	ne ASN Diversity, Equity, and Inclusion Committee for assistance with this session.
	avier Neyra, Sri Yarlagadda
2:00 p.m.	Supporting International Medical Graduates during Fellowship and Beyond – Koyal Jain
2:30 p.m.	Enhancing the Presence and Success of Faculty and Fellows Who Are Underrepresented in Medicine – Jason Cobb
3:00 p.m. 3:30 p.m.	Increasing Physician Scientists in Nephrology Fellowships – Samir Parikh Time for Action: How to Reduce Burnout in Nephrology – Charuhas Thakar

Friday, October 25, 4:30 p.m. – 6:00 p.m.

_	Digital Tools to Advance CKD Care and EducationBallroom 20D
	lay Koyner, Francis Wilson
4:30 p.m.	Artificial Intelligence and Machine Learning to Guide Clinical Decisions in Nephrology – Kianoush Kashani
4:50 p.m.	Artificial Intelligence in Nephrology Education: Ready for Prime Time? – Suzanne Boyle
5:10 p.m.	Identifying Bias in Artificial Intelligence and Machine Learning Algorithms: Does a Machine Have an Unconscious Bias? – Karandeep Singh
5:30 p.m.	CKD at Home: Mobile Applications and Wearable Devices – Michael Tadesse
	tion Science and Quality Improvement Efforts in AKI: Improving in Place Room 6B
	Michelle Starr, Julie Wright Nunes
4:30 p.m.	Learning Safety System: Applying Systems Engineering Principles in Critical Care Nephrology – Ayse Akcan Arikan
4:50 p.m.	Barriers and Facilitators of Successful Implementation of Evidence-Based
F.10 m m	Programs in AKI – Emily See
5:10 p.m.	Implementation Science in AKI Care: Tales from the Bedside – Oleksa Rewa
5:30 p.m.	Making Change at the Health-System Level: Post-Surgical AKI – Aarthi Vijaykumar
	Aditii vijaykuilidi
Advancing t	he Understanding of Proteinuria and eGFR as FSGS
_	End PointsRoom 6A
	ovided by an educational grant from Travere Therapeutics, Inc.
	Laura Mariani, Joshua Tarnoff
4:30 p.m.	Clinical Trials in FSGS: Where Have We Been and Where Are We Heading? –
4.50 p.m.	Daniel Gale
4:50 p.m.	Regulatory Pathways, Considerations, and the Application of Previous Work in Membranous Nephropathy and IgAN to FSGS – Aliza Thompson
5:10 p.m.	Modeling Proteinuria and eGFR Slope as Surrogate End Points for FSGS –
	Abigail Smith
5:30 p.m.	Panel Discussion: The Right Outcomes for Trials in FSGS – Rebecca Oag, Christine Sethna
	idney Transplant Longevity:
	echnologies on the Horizon
	Amishi Desai, Vineeta Kumar
4:30 p.m.	Refining Donor-Recipient Matching: Genome-Wide and Eplet-Based
4.50	Compatibility – Rainer Oberbauer
4:50 p.m.	Artificial Intelligence-Enhanced Interpretation of Kidney Transplant Biopsies –
F 10	Mariam Alexander
5:10 p.m.	Novel Approaches to Post-transplant Graft Assessment with Biosensors and
F 20	Biomarkers – Lorenzo Gallon
5:30 p.m.	Personalized Pharmacological Approaches to Prolong Kidney Allograft Survival –
	Gaurav Gupta
Precision Approaches to Diabetic Kidney Disease	
-	Morgan Grams, Christine Limonte
4:30 p.m.	From Circulating to Urinary Proteomics: Biomarkers of Diabetic Kidney Disease –
•	Monika Niewczas
4:50 p.m.	Metabolomics Approaches in Diabetic Kidney Disease – Kumar Sharma
5:10 p.m.	Through the Lens of the Kidney Precision Medicine Project – Matthias Kretzler
5:30 p.m.	Translational Biomarker Path in Diabetic Kidney Disease – Robert Nelson

Friday, October 25, 4:30 p.m. – 6:00 p.m.

ORAL ABSTRACT SESSIONS

CKD: Care Patterns and Novel Therapeutic Approaches
Cystic Kidney Diseases: Basic and Translational Research
Dialysis: What's New in Techniques and Management
Exercise and Kidney Health: From Bench to Smartphone Room 4 Moderators: Paul Bennett, Brandon Kistler
Glomerular Diseases: Mechanisms and More
Hypertension, CVD, and the Kidneys: Clinical Studies
IgA Nephropathy: New Therapies and InsightsRoom 6D Moderators: Shikha Wadhwani, Dia Waguespack
Innovative AKI Strategies and Drug Discoveries
Onconephrology: Models, Markers, and Medications
Pathology and Lab Medicine Advances
Women's Health and Kidney Diseases: From Bench to Bedside

Please refer to the meeting mobile app or the ASN website for the list of abstracts and presenters.



Introducing

ASN Kidney Health Guidance

• • • • • • • • • •

Management of Obesity in Persons Living with Kidney Diseases

From the experts who bring you:

ASN Kidney Week

The world's premier nephrology meeting

JASN, CJASN, and Kidney360

The most popular peer-reviewed journals

ASN Kidney News

The most widely distributed newsmagazine

ITE, BRCU, KSAP, and nephSAP

The leading resources for board success

Kidney Care Breakthroughs

KHI, KidneyX, and Kidney Cure fueling innovation

Advocacy Achievements

Legislative and regulatory victories

Excellence in Patient Care

Over 10 projects dedicated to advancing clinical care

Released September 18, 2024 and published in JASN

To learn more about ASN Kidney Health Guidance: www.asn-online.org/guidance

Poster Sessions Friday, October 25 | Exhibit Hall B

Poster Topics


NIII / NIIDDV and Informational Postars 2	INICOOL INICOLA
NIH/NIDDK and Informational Posters - 2	
Classroom to Bedside: Transforming Medical Education	
AKI: Epidemiology, Risk Factors, and Prevention - 2	
AKI: Diagnosis and Outcomes	
AKI: Mechanisms	
Onconephrology: Immunotherapy Nephrotoxicity and Assessment of GFR.	
Mineral Bone Disease: Transplant and Kidney Stones	
Diabetic Kidney Disease: Basic - 1	
Diabetic Kidney Disease: Clinical Modeling, Diagnosis, Education, and More	
Hypertension, CVD, and the Kidneys: Epidemiology	
Hemodialysis Epidemiology and Outcomes	
Home Dialysis - 1	
Dialysis Vascular Access	
Fluid, Electrolyte, and Acid-Base Disorders: Basic	
Cystic Kidney Diseases: Mechanisms and Models	
Genetic Kidney Diseases: Cohort Studies - Genetic Associations and Diagno	oses 636–679
Pediatric Nephrology - 1	
Glomerular Diseases: Mechanisms and Podocyte Biology	729–788
Glomerular Diseases: Inflammation and Immunology	789–848
IgA Nephropathy: Clinical, Outcomes, and Therapeutics	849–907
Glomerular Diseases: Potpourri	908–954
Pathology and Lab Medicine - 1	955–990
Transplantation: Basic	991–1018
Social, Environmental, and Economic Determinants of Kidney Health	1019–1047
Kidney Nutrition and Metabolism	1048–1080
CKD: Epidemiology, Risk Factors, and Prevention - 2	1081–1132
CKD: Kidney Function and Extrarenal Complications	1133–1174
CKD: Mechanisms - 2	1175–1222

Top Trainee Posters - 2

Friday, October 25 1:00-2:00 p.m.

Exhibit Hall B, Futures Theater

Note: Continuing education credits are not being offered for this activity.



Board #s

Shape the Future of Kidney Care with ASN



Join ASN and become part of a thriving community of nearly 22,000 nephrologists across 141 countries. As an ASN member, you'll access cutting-edge research, innovative educational resources, and exceptional networking opportunities, keeping you at the forefront of kidney care.

Exclusive Member Benefits:



Stay Informed: Enjoy subscriptions to ASN's premier publications— JASN, CJASN, Kidney360, and Kidney News. Get daily insights with In The Loop updates.



Save More: Access discounts on ASN events, programs, and Wolters Kluwer Nephrology Books, plus complimentary nephSAP issues and KSAP modules.



Connect and Grow: Dive into ASN Communities, utilize the ASN Career Center, and benefit from mentorship opportunities that drive professional development and collaboration.



Advance Your Career: Unlock eligibility for research grants, travel support, and other valuable opportunities.





Discover the Best of ASN Journals at Kidney Week 2024!

Join us for an unmissable session.

What to Expect:


Four editorial board members from ASN journals will showcase a selection of the high impact articles published over the past year. The session will cover key thematic areas, with the authors on hand to answer your questions.

Why Attend?

- Summarize Key Advances: Get a comprehensive overview of the highimpact research featured in ASN journals.
- Explore Therapeutic Breakthroughs: Learn about significant therapeutic advancements for kidney diseases.
- Understand Mechanistic Insights: Gain a deeper understanding of mechanistic studies that inform kidney disease treatment.

Thematic Areas:

AKI and Intensive Care Unit Nephrology, Glomerular Diseases, Therapeutic Advances in CKD, and Care of Patients Undergoing Long-Term Dialysis.



Don't miss this opportunity to engage with leading experts and enhance your knowledge of cutting-edge research in nephrology.

Mark your calendar and be there!

Date: October 25, 2024

Time: 2:00 p.m.

Location: Ballroom 20B/C



Day-at-a-Glance Saturday, October 26

0.00 0.30	
8:00 a.m. – 9:30 a.m.	
Plenary: Barbara T. Murphy Award, Belding H. Scribner Award, Homer W. Smith Award and Address, State-of-the-Art Lecture	Hall D
and Address, State-of-the-Art Lecture	
9:30 a.m. – 2:30 p.m. (Exhibit Halls)	
Morning Break (9:30 a.m. – 10:00 a.m.)	Exhibit Hall B
Scientific Exposition and Posters (9:30 a.m. – 2:30 p.m.)	
Poster Presentations by Authors (10:00 a.m. – 12:00 p.m.)	
Exhibitor Spotlights (10:00 a.m. – 1:45 p.m.)	
Please see pages 54-55 for spotlight schedule and topics.	
10:30 a.m. – 12:30 p.m.	
Basic/Clinical Science Sessions	
Beyond Antibody-Mediated Rejection: The Innate Immune System in	
Clinical Transplant Rejection, Including the Barbara T. Murphy, MB BAO BCh,	
Endowed LectureshipBa	Uroom 20B/C
Metabolic Communication and the Kidney Proximal Tubule	
Wetabolic Communication and the Ridney Froximal Tubule	100111 0D
Clinical Practice Sessions	
Conservative Kidney Management and Palliative Care across the Lifespan:	
When Less Is More	Ballroom 20D
Controversies in the Clinical Management of CKD-MBD	Room 7
Dialysis Quiz and Questionnaire	
Personalization and Precision in AKI Care	
Unraveling the Complexities of Heart Failure in Patients with Kidney Diseases -	
Honoring William Henrich	Room 5
Translational Sessions	
Expanding the Diagnostic Toolbox for Kidney Biopsy	Room 6A
New Era for Repurposing and Development of CKD Therapies for People	
Living with Type 1 Diabetes	Ballroom 20A
Oral Abstract Session	
High-Impact Clinical Trials - 2	Hall D
10:30 a.m. – 1:00 p.m.	
Top Trainee Posters - 3 (10:30 a.m. – 11:30 a.m.)Exhibit Hall B, Fu	tures Theater
Top Trainee Posters - 4 (12:00 p.m. – 1:00 p.m.)Exhibit Hall B, Fu	tures Theater
4	
12:45 p.m. – 1:45 p.m.	
Educational Symposia (Marriott Marquis San Diego Marina)	
Doors open at 12:30 p.m. Limited seating.	
Acute Kidney Dysfunction in Cirrhosis: A Case-Based Conversation about	
Diagnosis and TreatmentMarriott Gran	
Glucagon-Like Peptide-1 Receptor Agonists and Diabetic Kidney DiseaseMarriott Granc	d Ballroom 13
Targeting Cytokines in IgA Nephropathy:	
Understanding and Taking Aim at the "First-Hit"Marriott Gran	na Ballroom 8
2:00 p.m. – 4:00 p.m.	
Basic/Clinical Science Sessions	
Advances in the Molecular Genetics and Protein Dynamics Underlying Ciliopathies	Room 4
Hemodialysis-Induced Ischemia: Theoretical or Patient-Related Outcomes?	
Immune Cells and Inflammatory Signaling in AKI	

Molecular-Driven Management of Lupus Nephritis, One Cell at a Time......Room 6A

2:00 p.m. – 4:00 p.m.	
Basic/Clinical Science Sessions	
New Approaches to GFR: From Physiology to Bedside,	
Including the Barry M. Brenner, MD, Endowed Lectureship	Room 24
Novel Therapeutic Avenues to Explore for ADPKD and Autosomal Dominant	D 0
Tubulointerstitial Kidney Disease	
Recent Discoveries in Acid-Base Physiology	
Wrangling the RAAS in Kidney Diseases - Honoring Stephen Textor	KOOIII 5
Clinical Practice Sessions	
Nephrology Quiz and Questionnaire 2024	
Renal Biopsy: Clinical Correlations 2024	Room 1
Translational Sessions	
Complications of CKD-MBD: Classic and Nonclassic Effects.	
Including the Jack W. Coburn, MD, Endowed Lectureship	Room 7
Glomerular Disease Following Kidney Transplantation:	
Cutting-Edge Therapeutic Approaches	Ballroom 20B/C
Kidney Imaging for Improved CKD Diagnostics	
Mechanisms of Action for Kidney Protection with Novel Therapies for	
Diabetic Kidney Disease	Ballroom 20A
Other Event	
ASN Kidney Health Guidance: Today, Tomorrow, and Beyond	Room 8
7.514 Maney Fledian Saladnee. Foddy, Fornoriow, and Beyond	
4:00 p.m. – 4:30 p.m.	
4:00 p.m. – 4:30 p.m. Afternoon BreakFoyers of Ballroom	n 20 and Room 6A
	n 20 and Room 6A
Afternoon BreakFoyers of Ballroom	n 20 and Room 6A
Afternoon BreakFoyers of Ballroom 4:30 p.m. – 6:00 p.m.	
Afternoon Break	Ballroom 20B/C
Afternoon Break	Ballroom 20B/C Room 6B Ballroom 20A
Afternoon Break	Ballroom 20B/CRoom 6BBallroom 20A
Afternoon Break	Ballroom 20B/CRoom 6BBallroom 20A
Afternoon Break	Ballroom 20B/CRoom 6BBallroom 20ABallroom 20DBallroom 6A
Afternoon Break	Ballroom 20B/CRoom 6BBallroom 20ABallroom 20DBallroom 6A
Afternoon Break	Ballroom 20B/CRoom 6BBallroom 20ABallroom 20DRoom 6ARoom 5Room 2
Afternoon Break	Ballroom 20B/CRoom 6BBallroom 20ABallroom 20DRoom 6ARoom 5Room 2
Afternoon Break	Ballroom 20B/CBallroom 20ABallroom 20DBallroom 20DRoom 6ARoom 5Room 2Room 2Room 24Room 7
Afternoon Break	Ballroom 20B/CBallroom 20ABallroom 20DRoom 6ARoom 5Room 2Room 2Room 24Room 7Room 8
Afternoon Break	Ballroom 20B/CBallroom 20ABallroom 20DRoom 6ARoom 5Room 2Room 2Room 24Room 7Room 8Room 4
Afternoon Break	Ballroom 20B/CBallroom 20ABallroom 20DRoom 6ARoom 5Room 2Room 2Room 7Room 8Room 4Room 1
Afternoon Break	Ballroom 20B/CBallroom 20ABallroom 20DRoom 6ARoom 5Room 5Room 2Room 24Room 7Room 8Room 4Room 1Room 6D
Afternoon Break	Ballroom 20B/CBallroom 20ABallroom 20DRoom 6ARoom 6ARoom 5Room 2Room 24Room 7Room 8Room 4Room 1Room 6DRoom 23



For current meeting information search for "ASN Kidney Week" in your app store or scan this QR code.



Saturday, October 26, 8:00 a.m. – 9:30 a.m.

Plenary	Hall D
Support is provided by an educational grant from Vera Therapeutics.	
8:00 a.m.	Barbara T. Murphy Award – Vesna D. Garovic
8:15 a.m.	Belding H. Scribner Award – Claudio Ronco
8:30 a.m.	Homer W. Smith Award and Address "AKI, Repair, and Generation of Kidney
0.50 4.111.	Tissue" – Joseph Bonventre
9:00 a.m.	State-of-the-Art Lecture "Understanding, Improving, and Applying Human
	Pluripotent Stem Cell-Derived Kidney Tissues" – Melissa Little
	,,
	Saturday, October 26, 10:30 a.m. – 12:30 p.m.
Beyond Antik	pody-Mediated Rejection: The Innate Immune System in
Clinical Trans	plant Rejection, Including the Barbara T. Murphy, MB BAO BCh,
Endowed Lec	tureshipBallroom 20B/C
	acknowledges Verici Dx, Renalytix, and the American Society of Transplantation for
	Murphy Endowed Lectureship.
	licolae Leca, Zheng Zhang
10:30 a.m.	Innate Immune Cells in Transplant Rejection: What We Know – Xun-Rong Luo
11:00 a.m.	Molecular Profiling of Kidney Allograft Biopsy: The Long Shadow of Innate
	Immune Receptors and Cells – Jasper Callemeyn
11:30 a.m.	Microvascular Inflammation without Donor-Specific Antibodies:
	Is It Antibody-Mediated Rejection or Something Else? – Olivier Thaunat
12:00 p.m.	Selective Targeting of the Innate Immune System in Transplantation:
p	The Time Is Now: The Barbara T. Murphy, MB BAO BCh, Endowed Lectureship –
	Fadi Lakkis
	Tuul Eurkis
Metabolic Co	mmunication and the Kidney Proximal TubuleRoom 6D
	Christine Klemens, Prabhleen Singh
10:30 a.m.	Ketones and the Kidneys: Fuel for Tubular Metabolic Cross-Talk – Sarah Huen
11:00 a.m.	Metabolic Communication by SGLT2 Inhibition – Markus Rinschen
11:30 a.m.	Role of Tryptophan Metabolism in Kidney Diseases – Pinelopi Kapitsinou
12:00 p.m.	Metabolite Secretion by the Proximal Tubule: Importance and Clinical
12.00 p.111.	Applications – Bryan Kestenbaum
	Applications - Bryan Restendanti
Conservative	Kidney Management and Palliative Care across the Lifespan:
	More
	Ilvin Moss, Devika Nair
10:30 a.m.	Integrating Conservative Management into Adult Nephrology Practice –
10.50 a.m.	Jane Schell
11:00 a.m.	Palliative Care Approaches for Children with Kidney Diseases – Aaron Wightman
11:30 a.m.	Time-Limited Trials of Dialysis: Why, When, and How? – Jennifer Scherer
12:00 p.m.	A Patient's Perspective on Palliative Dialysis – David Rush
12.00 p.111.	A ratione of Cospective on ramative budysis barra Nasir
Controversies	s in the Clinical Management of CKD-MBDRoom 7
	Orlando Gutierrez, Julia Scialla
10:30 a.m.	To Treat or Not to Treat Hyperphosphatemia (to Target): Pro – Joachim Ix
11:00 a.m.	To Treat or Not to Treat Hyperphosphatemia (to Target): Con – Michael Walsh
11:30 a.m.	Who's on First? First-Line Treatment in Secondary Hyperparathyroidism in
11.50 a.iii.	ESKD: Calcimimetics – Sharon Moe
12:00 p.m.	Who's on First? First-Line Treatment in Secondary Hyperparathyroidism in
12.00 p.111.	ESKD: Vitamin D Analogues – Markus Ketteler

Saturday, October 26, 10:30 a.m. – 12:30 p.m.

ASN thanks th	and Questionnaire
Moderators: C 10:30 a.m.	Christopher Chan, Jenny Shen Ultrafiltration in Hemodialysis: Too High, Too Low, Too Fast - Where Do
11:00 a.m.	We Go? – Jennifer Flythe Leaks and Lumps and Bumps, Oh My: Noninfectious Complications in Peritoneal Dialysis – Joanne Bargman
11:30 a.m.	Hemodialysis Vascular Access Complications: A Case-Based Discussion – Monnie Wasse
12:00 p.m.	Home Hemodialysis: When Not to Be Too Prescriptive – Joel Glickman
Personalizati	on and Precision in AKI CareRoom 6B
ASN thanks th	e ASN AKINow Recovery Workgroup for assistance with this session.
Moderators: Jo	onathan Himmelfarb, Jennifer Schaub
10:30 a.m.	Defining AKI Subphenotypes: Artificial Intelligence and Beyond – Kathleen Liu
11:00 a.m.	How Can AKI Biomarkers Help Inform Individualized Care? – Jay Koyner
11:30 a.m.	Strategies to Promote Recovery in AKI Requiring Dialysis: Personalized Fluid
	Management and De-escalation – Samuel Silver
12:00 p.m.	Meeting Patients in Their Place: Individualizing AKI Education to Improve
•	Outcomes – Jia Hwei Ng
Unraveling th	ne Complexities of Heart Failure in Patients with Kidney Diseases -
	lliam HenrichRoom 5
ASN thanks th	e European Renal Association (ERA) and ERA Ambassador, Dr. Christoph Wanner.
	anani Rangaswami, Bethany Roehm
10:30 a.m.	Novel Mechanisms and Approaches to Diuretic Resistance in Cardiorenal
	Syndrome: In Memory of William Henrich – David Ellison
11:00 a.m.	SGLT2 Inhibitors to Augment Diuresis in Acute Heart Failure – Adeera Levin
11:30 a.m.	Implementing Guideline-Directed Medical Therapy in Patients with Kidney
	Diseases and Heart Failure – Christoph Wanner
12:00 p.m.	Blood Volume Regulation and Cardiorenal Syndrome: From Bench to Bedside –
p	Kaushik Patel
Expanding th	e Diagnostic Toolbox for Kidney BiopsyRoom 6A
	ilarissa Cassol, Jeffrey Hodgin
10:30 a.m.	Laser Capture Microdissection and Mass Spectrometry in Glomerular Diseases –
. 0.00 0	Sanjeev Sethi
11:00 a.m.	Digital Pathology Repository Creation and Consensus Achievement –
11.00 0.111.	Cynthia Nast
11:30 a.m.	Spatial Transcriptomics as a Diagnostic Tool: Are We There Yet? –
11.50 a.m.	Shreeram Akilesh
12:00 p.m.	Potential Applications of Artificial Intelligence-Based Technology in Kidney
12.00 p.111.	Pathology – Pinaki Sarder

Saturday, October 26, 10:30 a.m. – 12:30 p.m.

	·
New Era for I	Repurposing and Development of CKD Therapies for People
	ype 1 DiabetesBallroom 20A
_	Villiam Herrington, Vikas Sridhar
10:30 a.m.	SGLT2 Inhibition and the Potential for Preventing Cardiorenal Complications in
	Type 1 Diabetes – Alessandro Doria
11:00 a.m.	Finerenone and Mineralocorticoid Receptor Antagonists in Type 1 Diabetes:
	Past, Present, and Future – M. Luiza Caramori
11:30 a.m.	Incretins and Kidney Protection in Type 1 Diabetes – Ian De Boer
12:00 p.m.	Real-World Evidence of Efficacy and Safety of Adjunctive Therapies for Type 1
•	Diabetes – Frederik Persson
	Clinical Trials - 2 Hall D
Please check t	he meeting mobile app or the ASN website for the list of abstracts and presenters.
	Saturday, October 26, 12:45 p.m. – 1:45 p.m.
	Educational Symposia (Marriott Marquis San Diego Marina)
	Doors open at 12:30 p.m. Lunch is provided.
Lir	nited seating; first-come, first-served to fully paid Annual Meeting participants.
	Dysfunction in Cirrhosis:
	Conversation about Diagnosis and Treatment Marriott Grand Ballroom 5
	vided by an educational grant from Mallinckrodt Pharmaceuticals.
12:45 p.m.	Introduction – Heather May (Moderator)
12:55 p.m.	The Differential Dance: A Case-Based Discussion of Etiologies and Mechanisms
	of Acute Kidney Dysfunction in Cirrhosis – Neesh Pannu
1:15 p.m.	Mastering Management: A Case-Based Discussion of Therapies for Acute
	Kidney Dysfunction in Cirrhosis – Mitra Nadim
1:35 p.m.	Questions and Answers
Character 131	Double 4 December Associate and
	re Peptide-1 Receptor Agonists and
	ney Disease
	vided by an educational grant from Novo Nordisk.
12:45 p.m.	Introduction – Subramaniam Pennathur (Moderator) GLP-1 RAs in Diabetic Kidney Disease: Focus on Kidney Outcomes –
12:55 p.m.	•
1.15	Peter Rossing
1:15 p.m.	GLP-1 RAs: On the Mechanisms of Renoprotection – Radica Alicic
1:35 p.m.	Questions and Answers
Targeting Cv	tokines in IgA Nephropathy:
	ng and Taking Aim at the "First-Hit"8
	vided by an educational grant from Vera Therapeutics.
12:45 p.m.	Introduction – Lavinia Negrea (Moderator)
12:45 p.m.	The Pathogenic Role of Cytokines BAFF and APRIL in IgAN – Bobby Chacko
1:15 p.m.	Treatment Strategies Targeting the First Hit in IgAN – Fernando Fervenza
1.15 p.111. 1:35 p.m	Ouestions and Answers

Saturday, October 26, 2:00 p.m. – 4:00 p.m.

	the Molecular Genetics and Protein Dynamics Underlying Ciliopathies Room 4
	rica Davis, Pamela Tran
2:00 p.m.	Molecular Genetics of the Ciliopathies: Challenges and Opportunities – Jeremy Reiter
2:30 p.m.	Elucidating Functional Cellular Modules and Protein Networks in Ciliopathies – Ronald Roepman
3:00 p.m.	Functional Proteomics and Live-Cell Microscopy to Understand Cellular Dynamics in Ciliopathies – Julie Van De Weghe
3:30 p.m.	Extraciliary Roles for Established Ciliary Proteins – Helen May-Simera
	s-Induced Ischemia: Theoretical or Patient-Related Outcomes?Room 6C
	ane Davis, Suzanne Norby
2:00 p.m.	Hemodialysis-Induced Multiorgan Ischemia – Christopher McIntyre
2:30 p.m.	Consequences and Mitigation of Cardiac Stunning – James Burton
3:00 p.m.	Cerebral Blood Flow and Cognitive Function – Dawn Wolfgram
3:30 p.m.	Can Intradialytic Exercise Mitigate Hemodialysis-Induced Myocardial Stunning in Clinical Settings? – Clara Bohm
	s and Inflammatory Signaling in AKIRoom 6B
	inelopi Kapitsinou, Sho Morioka
2:00 p.m.	Immune Landscape in AKI – Leyuan Xu
2:30 p.m.	Macrophage Diversity in AKI – Jamie Privratsky
3:00 p.m.	T Cells in AKI – Hamid Rabb
3:30 p.m.	Clonal Hematopoiesis of Indeterminate Potential and Risk of AKI –
	Caitlyn Vlasschaert
	riven Management of Lupus Nephritis, One Cell at a TimeRoom 6A
	vided by an educational grant from Travere Therapeutics, Inc.
	alem Almaani, Craig Gordon
2:00 p.m.	Catching Lupus Nephritis Molecular Program In Flagranti: Lessons Learned
2.20	from Accelerating Medicines Partnership Biopsies – Soumya Raychaudhuri
2:30 p.m.	Lupus Nephritis Activity and Treatment Response in Peripheral Blood
2:00 n m	Lymphocytes: Deep Immune-Cell Profiling – Alice Horisberger
3:00 p.m.	Urine Proteomics and Liquid Kidney Biopsy in Systemic Lupus Erythematosus – Andrea Fava
3:30 p.m.	Developing Targeted Treatments for Lupus Nephritis: Time for Precision Trials –
3.30 p.m.	Liz Lightstone
	ches to GFR: From Physiology to Bedside,
	Barry M. Brenner, MD, Endowed LectureshipRoom 24
	v acknowledges Monarch Pharmaceuticals for support of the Brenner Endowed Lectureship.
	Cirk Campbell, Aylin Rodan
2:00 p.m.	Unraveling the Mysteries of High GFR in Health and Disease: The Barry M. Brenner, MD, Endowed Lectureship – Timothy Meyer
2·30 n m	GFR Stress Test: Assessing Kidney Reserve in CKD – Bruce Molitoris
2:30 p.m. 3:00 p.m.	Direct Measurement of GFR in the Clinic – Elke Schaeffner
3:30 p.m.	GFR Assessment in the Transition from Pediatric to Adult Nephrology:
5.50 p.111.	er it reconstruction the franction from reduction to Addit Repliedby.

Saturday, October 26, 2:00 p.m. – 4:00 p.m.

Tubulointerst	eutic Avenues to Explore for ADPKD and Autosomal Dominant itial Kidney DiseaseRoom 2 aram Aboudehen. Fouad Chebib
2:00 p.m.	Role of PKD1 Upstream Open Reading Frames in Polycystin Dosage: A Potential Therapeutic Avenue? – Whitney Besse
2:30 p.m. 3:00 p.m. 3:30 p.m.	Immune and Metabolic Rewiring to Treat ADPKD – Katharina Hopp Role of Intracellular Cholesterol Biosynthesis in ADPKD – Ronak Lakhia Mesencephalic Astrocyte-Derived Neurotrophic Factor for Treatment of Protein Misfolding Diseases: ADTKD – Ying Chen
Recent Discov	veries in Acid-Base PhysiologyRoom 6D
	ylvie Breton, Brandi Wynne
2:00 p.m.	Redefining "Bicarbonate" Transport – Walter Boron
2:30 p.m.	Acid-Base Sensing by AE4 – Helga Vitzthum
3:00 p.m.	Role of V-ATPase B1 Subunit in Metabolic Alkalosis – Carsten Wagner
3:30 p.m.	Secretin and the Alkaline Tide – Jens Leipziger
	e RAAS in Kidney Diseases - Honoring Stephen TextorRoom 5
2:00 p.m.	Aldosterone Synthase Inhibition as a "New Kid on the Block" in Hypertension
2.00 p.111.	and CKD Treatment – M. Luiza Caramori
2:30 p.m.	Full Circle View of Mineralocorticoid Receptor Antagonism for Treatment of
2.50 p	CKD and ESKD – Rajiv Agarwal
3:00 p.m.	Primary Aldosteronism in CKD: Are We Missing the Mark? – Debbie Cohen
3:30 p.m.	Sexually-Dimorphic Responses to Aldosterone Antagonism in Hypertensive
·	Kidneys – Mykola Mamenko
Nephrology C	Quiz and Questionnaire 2024Ballroom 20D
Moderators: Be	eatrice Concepcion, Roger Rodby
2:00 p.m.	Electrolyte and Acid-Base Disturbances – Juan Carlos Velez
2:30 p.m.	Glomerular Diseases – Timothy Yau
3:00 p.m.	Transplantation – Julie Ho
3:30 p.m.	CKD and Kidney Replacement Therapy – Anna Burgner
Renal Biopsy:	Clinical Correlations 2024
ASN thanks the	e Renal Pathology Society for assistance with this session.
	Digital Pathology Room is provided by Otsuka America Pharmaceutical, Inc.
Moderators: N	icole Andeen, Laura Biederman Clinical Discussant: Gearoid McMahon
2:00 p.m.	Renal Pathology Case Study 1 – Jonathan Zuckerman
2:30 p.m.	Renal Pathology Case Study 2 – Satoru Kudose
3:00 p.m.	Renal Pathology Case Study 3 – Laura Finn
3:30 p.m.	Renal Pathology Case Study 4 – Ritu Gupta
	s of CKD-MBD: Classic and Nonclassic Effects,
	Jack W. Coburn, MD, Endowed LectureshipRoom 7
	acknowledges Amgen for support of the Coburn Endowed Lectureship.
	naron Moe, Katherine Wesseling-Perry
2:00 p.m.	CKD-MBD and the Gut Connection – Peter Stenvinkel
2:30 p.m.	CKD-MBD and the Muscle System – Christian Faul
3:00 p.m.	CKD-MBD and the Heart – Maren Leifheit-Nestler
3:30 p.m.	CKD-MBD and the Skeleton: The Jack W. Coburn, MD, Endowed Lectureship –
	Thomas Nickolas

Saturday, October 26, 2:00 p.m. – 4:00 p.m.

	isease Following Kidney Transplantation:
	Therapeutic Approaches
	e European Renal Association (ERA) and ERA Ambassador, Dr. Olivier Aubert.
	arin True, Alexander Wiseman
2:00 p.m.	Current and Novel Approaches to the Treatment of Recurrent FSGS after
2.20	Transplant – Flavio Vincenti
2:30 p.m.	Clinical Approaches for the Prevention and Treatment of Recurrent Atypical
2,00 10 100	Hemolytic Uremic Syndrome and C3 Glomerulopathy – Carla Nester
3:00 p.m.	Prevention of Diabetic Nephropathy after Kidney Transplant:
2,20 5 55	State-of-the-Art Care Considerations – Sunita Singh
3:30 p.m.	Understanding Transplant Glomerulopathy beyond Histology:
	Implications for Intervention – Olivier Aubert
Kidney Imagi	ng for Improved CKD DiagnosticsRoom 23
Moderators: E	mily Chang, Pablo Ortiz
2:00 p.m.	Emerging Diagnostic and Therapeutic Imaging Strategies – Barbara Klinkhammer
2:30 p.m.	Using CT to Noninvasively Measure Kidney Hemodynamics – Alejandro Chade
3:00 p.m.	Functional MRI in Nephrology – Kevin Bennett
3:30 p.m.	Noninvasive Imaging Biomarkers to Diagnose CKD – Anand Srivastava
	of Action for Kidney Protection with Novel Therapies for
Diabetic Kidn	ey DiseaseBallroom 20A
Moderators: A	deera Levin, Ayodele Odutayo
2:00 p.m.	SGLT2 Inhibition and Kidney Protection: Bench to Bedside – Mark Cooper
2:30 p.m.	Incretin-Based Therapies and Kidney Protection: Beyond Weight Loss –
	Daniël van Raalte
3:00 p.m.	Nonsteroidal Mineralocorticoid Receptor Antagonists and Kidney Protection:
	From Single Cell to Hemodynamics – Katalin Susztak
3:30 p.m.	Goal-Directed Physiological Therapies and the Rationale for Combining Novel
	Diabetic Kidney Disease Therapies – Brendon Neuen
ASN Kidney I	Health Guidance: Today, Tomorrow, and BeyondRoom 8
	ing education credits are not being offered for this activity.
	Pavid Ellison, Holly Kramer
2:00 p.m.	Advancing Clinical Care through ASN Kidney Health Guidance:
2.00 p	Importance, Differentiation, and Innovation – Kathleen Liu
2:30 p.m.	Changing the Dialogue for Nephrology Care in the Management of Obesity in
p	Persons Living with Kidney Diseases – Talat Alp Ikizler
3:00 p.m.	The Future of ASN Kidney Health Guidance: Highlighting the Development
•	Pipeline for 2025 and Beyond, Outlining the Process for Nominating Topics,
	and Prioritizing Dissemination – Sarah Sampsel
3:30 p.m.	Developing Patient-Directed Clinical Guidance: Incorporating the Patient
•	Perspective into Clinical Care – John Ortiz

Saturday, October 26, 4:30 p.m. – 6:00 p.m.

Health Equit	ty Topics in CKD Ballroom 20B/C
	Rudolph Rodriguez, Milda Saunders
4:30 p.m.	CKD in Native Hawaiians and Pacific Islanders – Reya Mokiao
4:50 p.m.	Multifaceted Approaches to Mitigate Kidney Diseases in American Indians and
	Alaska Natives – Jason Deen
5:10 p.m.	Intersection of Age, Sex, and Racial Disparities in Kidney Transplant Access –
F-20	Mara McAdams-DeMarco
5:30 p.m.	How to Improve Representation in Nephrology Research Studies – Susanne Nicholas
Point-of-Ca	re Ultrasonography in Nephrology:
Where Are \	We and Where Are We Heading?Room 6B
Moderators:	Eduardo Argaiz, Elaine Kaptein
4:30 p.m.	POCUS Mastery Blueprint: Crafting a Competency-Driven Longitudinal
	Curriculum – Abhilash Koratala
4:50 p.m.	POCUS-Assisted Volume Status in Hemodialysis: Possibilities and Limitations – Nathaniel Reisinger
F.10 m m	3
5:10 p.m.	POCUS in Evolving Specialties: Insights from an Onconephrologist – Bhavna Bhasin-Chhabra
5:30 p.m.	Cardiac and Lung Ultrasonography for the Nephrologist: Moving beyond
	Isolated Organ Imaging – Anju Yadav
	ectations about Dialysis-Related SymptomsBallroom 20A
	Mary Baliker, Manisha Jhamb
4:30 p.m.	Post-dialysis Fatigue: Causes and Consequences – Lucile Parker Gregg
4:50 p.m.	Causes and Consequences of Dialysis-Related Cramping – Michelle Richardson
5:10 p.m.	Measuring Dialysis-Related Symptoms: Are We Getting It Right? – Mark Unruh
5:30 p.m.	Does Dialysis Modality Make a Difference in Symptoms?
	Setting Patient Expectations – Yuvaram Reddy
	ting Therapies across NephrologyBallroom 20D
	Moumita Barua, Eun ji Chung
4:30 p.m.	360° View of Gene Therapy for CKD – Matthew Wilson
4:50 p.m.	Gene Therapy Targeting the Podocyte: Monogenic Disease and Beyond – Moin Saleem
5:10 p.m.	Targeting MicroRNA for the Treatment of PKD – Vishal Patel
5:30 p.m.	Gene-Targeted Therapy for Hyperoxaluria: Results from Recent Clinical Trials – Mini Michael
	es for Therapeutics Targeting the Glomerular Filtration BarrierRoom 6A
	ovided by an educational grant from Travere Therapeutics, Inc.
	Gabriel Cara-Fuentes, Mira Krendel
4:30 p.m.	Glomerular Filtration Barrier Inside Out: New Insights from Imaging – Janos Peti-Peterdi
4:50 p.m.	Insights from Building the Glomerular Filtration Barrier – Evren Azeloglu
5:10 p.m.	Glomerular Basement Membrane Components in Glomerular Function and
'	Diseases – Jeffrey Miner
5:30 p.m.	Targeted Treatments for the Glomerular Filtration Barrier – Alessia Fornoni

Saturday, October 26, 4:30 p.m. – 6:00 p.m.

ORAL ABSTRACT SESSIONS

AKI: An Inflamed State of the Union
Bioengineered Model Systems and Insights in Kidney Development and Function
CKD: New Insights into Mechanisms and Treatment Strategies
Diabetic Kidney Disease - Basic: Discovery to Translational Science
Dialysis Vascular Access: Research Advances
Fluid, Electrolyte, and Acid-Base Disorders: Clinical Advances
Moderators: Niralee Patel, Joshua Rein
Moderators: Niralee Patel, Joshua Rein Glomerular Diseases: All about Podocytes
Moderators: Niralee Patel, Joshua Rein Glomerular Diseases: All about Podocytes

Please refer to the meeting mobile app or the ASN website for the list of abstracts and presenters.

Poster Sessions Saturday, October 26 | Exhibit Hall B

Poster Topics	Board #s
NIH/NIDDK and Informational Posters - 3	INICOO1 INICO12
Augmented Intelligence, Large Language Models, and Digital Health	
AKI: Clinical, Outcomes, and Trials - Management	
AKI: Inflammation and Cell Cycle	
	111-100
Onconephrology: Kidney Outcomes during Cancer Treatment and Nephropathies	167 222
CKD-MBD: Basic and Translational	
Diabetic Kidney Disease: Basic - 2	
Diabetic Kidney Disease: Clinical Pathology, Diagnostic	234–232
and Treatment Advances	203 ⁻ 331
Hypertension, CVD, and the Kidneys: Clinical Research	
Hemodialysis and Frequent Dialysis - 2	
Home Dialysis - 2	
Acid-Base, Calcium, Potassium, and Magnesium Disorders: Clinical	
Bioengineering	
Cystic Kidney Diseases: Genetic Causes, Modifiers, and Extrarenal Manifest	
Genetic Kidney Diseases: Models, Mechanisms, and Therapies	
Pediatric Nephrology - 2	
Glomerular Diseases: Therapeutic Strategies	
ANCA-Associated Vasculitis, Anti-GBM Disease, and Other RPGN	
C3G, TMA, MGRS, Amyloidosis, and More	
Glomerular Diseases: Case Reports - 2	
Pathology and Lab Medicine - 2	907–939
Transplantation: Clinical - 3	940–991
Transplantation: Clinical - 4	992–1040
Women's Health and Kidney Diseases	1041–1063
CKD: Epidemiology, Risk Factors, and Prevention - 3	1064–1111
CKD: Patient-Oriented Care and Case Reports	
CKD: Mechanisms - 3	1159–1202

Top Trainee Posters - 3 and 4

Saturday, October 26 10:30-11:30 a.m.

Saturday, October 26 12:00-1:00 p.m.

Exhibit Hall B, Futures Theater

Note: Continuing education credits are not being offered for this activity.



Discover the Future of Kidney Care at the Scientific Exposition

Exhibit Halls A-C (Enter at Hall B)

Join ASN at the cornerstone of Kidney Week—where innovation meets inspiration. The Scientific Exposition is your gateway to exploring the latest advancements and technologies in kidney care. Engage with over 145 exhibiting companies, experience cutting-edge demonstrations, and network with professionals who share your commitment to advancing patient care. From pharmaceutical breakthroughs to imaging innovations, this is where the future of kidney care comes to life.

Highlights include:

- Over 145 Exhibiting Companies
- ASN Career Fair
- ASN Communities Lounge
- Attendee Lounges
- Headshot Lounge
- Complimentary Refreshment Breaks

- 12 Exhibitor Spotlights
- Fellows-in-Training (FIT) Bowl
- 3,000+ Posters with Moderated Poster Sessions
- Welcome Reception
- Wi-Fi Service

Exhibit Hall and Poster Schedule

Thursday, October 24 9:30 a.m. - 2:30 p.m. Friday, October 25 9:30 a.m. - 2:30 p.m. Saturday, October 26 9:30 a.m. - 2:30 p.m.

Welcome Reception

Thursday, October 24 6:00 - 7:00 p.m.

Attendee Lounges and Exhibit Hall Refreshment Breaks are supported by Ardelyx, Inc.

The Welcome Reception and Headshot Lounge are supported by Calliditas Therapeutics.



Exhibitor Spotlight Schedule

Thursday, October 24 - Saturday, October 26

Exhibit Hall

Join your colleagues for the latest advances in nephrology practices, products, services, and technologies presented in two theaters on the exhibit hall floor. Seating is limited and available on a first-come, first-served basis.

The 10:00 a.m. presentations include breakfast. All other presentations include lunch.

Thursday, October 24

10:00-10:45 a.m.

Theater 1

Helping Patients Go Home Successfully: The Home Dialysis Spotlight!

Presented by Rayter

11:00-11:45 a.m.

Theater 2

Jardiance® (empagliflozin) tablets: Expert Perspectives on Clinical Trial Data and Approved Indications





12:00-12:45 p.m.

Theater 1

A Stronger Foundation: Perspectives on an IgA Nephropathy Therapy with an Updated Indication



1:00-1:45 p.m.

Theater 2

Discover an Innovative Mechanism of Action: An Oral, Once-Daily HIF-PHI

Presented by Akebia



Friday, October 25

10:00-10:45 a.m.

Theater 1

Navigating IgA Nephropathy: Pathogenesis, the Role of APRIL, and Patient Case Study



11:00-11:45 a.m.

Theater 2

A Different Perspective on Hyperphosphatemia Management: **Evaluating Current Strategies**



Friday, October 25

12:00-12:45 p.m.

Theater 1

Get to Know FABHALTA® (iptacopan)

Presented by **NOVARTIS**

1:00-1:45 p.m.

Theater 2

Early Intervention in IgA Nephropathy: An Update on a Potential Disease-Modifying Therapy

Presented by Calliditas

Saturday, October 26

10:00-10:45 a.m.

Theater 1

Transitions of Care in Kidney Transplant with ENVARSUS XR®



11:00-11:45 a.m.

Theater 2

Effective Strategies with HIF PH Inhibitors: Insights from Real-World Evidence



12:00-12:45 p.m.

Theater 1

Rare Disease Across the Lifespan: Helping Patients with Cystinosis Thrive into Adulthood

Presented by **AMGEN**

1:00-1:45 p.m.

Theater 2

Potential Approaches to Addressing the Autoimmunity in Autoimmune Glomerulonephritis

Presented by VERTEX



These events are not CE (continuing education) activities.



Day-at-a-Glance **Sunday, October 27**

8:00 a.m. – 9:00 a.m.	
Plenary: ASN Midcareer Awards, In Memoriam, State-of-the-Art Lecture	Hall D
ASN Business Meeting	Hall D
9:30 a.m. – 11:30 a.m.	
Basic/Clinical Science Sessions	
Everything Starts within the Graft	Room 7
Swollen Feet: Immune Mechanisms of Glomerular Diseases	Room 8
Transcriptional Control in AKI Recovery	Room 4
Unraveling C3 Glomerulopathy: Insights into Diagnosis, Management, and	
Therapeutic Strategies	Room 6A
Clinical Practice Sessions	
AKI Management in Critically III Patients	Room 6B
Clinical Management of Patients with Genetic Kidney Diseases	Room 2
Medication Debates in CKD	Room 6C
Practical Management of Hypertension: Novel Approaches and Therapies	
Transitions in Home Dialysis	Room 1
Translational Session	
Diabetic Kidneys and Interorgan Cross-Talk	Room 6D

Kidney Week On-Demand

Never miss a session with Kidney Week *On-Demand* 2024. With over 250 hours of recorded Annual Meeting presentations, this resource is the best way to get the most out of your meeting experience.

To get your complimentary access code, exchange the voucher in your meeting bag at one of the booths listed below.







Booth 2321

Booth 1729



Access codes are available during Exhibit Hall hours to fully paid Annual Meeting participants only. All recorded presentations will be available in late November.

Sunday, October 27, 8:00 a.m. – 9:00 a.m.	
Plenary	Hall D
Support is pro	ovided by an educational grant from Vera Therapeutics.
8:00 a.m.	ASN Midcareer Awards
8:15 a.m.	In Memoriam
8:30 a.m.	State-of-the-Art Lecture "The Curative Therapy for Sickle Cell Disease:
	The Good, The Bad, and The Future" – Michael DeBaun
ASN Busines	ss MeetingHall D
Note: Contin	uing education credits are not being offered for this activity.

	g
	Sunday, October 27, 9:30 a.m. – 11:30 a.m.
Everything Starts within the Graft	
Moderators: D	Parshana Dadhania, Rania El Fekih
9:30 a.m.	Transcriptomic Profiling of Kidney Allograft: Where Does the Injury Start? –
	Valeria Mas
10:00 a.m.	Epigenetic Profiling of Kidney Allografts – Paul Shiels
10:30 a.m.	Metabolomic Profiling – Paolo Cravedi
11:00 a.m.	Role of Interleukin-33 in Immunological Profiling – Heth Turnquist
Swollen Feet	Immune Mechanisms of Glomerular DiseasesRoom 8
Support is pro	vided by an educational grant from Travere Therapeutics, Inc.
Moderators: C	Christoph Licht, Mariya Sweetwyne
9:30 a.m.	New Insights and Therapeutic Opportunities in Immune-Mediated Glomerular
	Diseases: The 30,000-Foot View – Tingting Li
10:00 a.m.	Rare Pathogenic Variants in Interleukin-15 Drive Podocyte Injury and
	Development of FSGS – Gentzon Hall
10:30 a.m.	Reconsidering Popular Notions: Exploring the Paradoxical Role of Interleukin-1
	and Interleukin-1 Receptor in Podocyte Protection – Jiafa Ren
11:00 a.m.	Not So Minimal a Change: Updates on the Role of Anti-nephrin Antibodies in
	Nephrotic Syndrome – Astrid Weins
	10 . 11 . 110
	al Control in AKI Recovery
	e ASN AKINow Basic Science Workgroup for assistance with this session.
	ierre Dagher, Anna Greka
9:30 a.m.	Extracting Gene Regulatory Signatures from Multi-Omic Data –
10.00	Julio Saez-Rodriguez
10:00 a.m.	Transcriptional Pausing and Stress Control in the Kidneys – Jason Watts
10:30 a.m.	Transcriptional Control of Recovery in Human AKI: Insights from the Kidney
44.00	Precision Medicine Project – Jennifer Schaub
11:00 a.m.	Ischemic and Toxic Nephron in Transplanted Kidneys – Sanjeev Kumar

Sunday, October 27, 9:30 a.m. – 11:30 a.m.

Therapeutic Sci ASN thanks the Support is prove Moderators: Ca 9:30 a.m. 10:00 a.m.	Glomerulopathy: Insights into Diagnosis, Management, and trategies
11:00 a.m.	Defining Effective End Points for C3 Glomerulopathy – Daniel Gale
_	ent in Critically III PatientsRoom 6B
	rtrick Murray, Edward Siew
9:30 a.m.	Fluid Tolerance and Responsiveness in Critically III Patients with AKI – Michael Connor
	Vasopressor Optimization in AKI – Raghavan Murugan
10:30 a.m.	Management of AKI after Cardiac Arrest – Sarah Sanghavi
11:00 a.m.	The Nephrologist's Role in Managing Hyperammonemia: Liver Failure and Beyond – Danielle Saly
Clinical Manag	gement of Patients with Genetic Kidney Diseases Room 2
	nthony Bleyer, Amar Majmundar
9:30 a.m.	Genetic Resources for the Clinician: Variant Databases and Curation – Andrew Mallett
10:00 a.m.	Role of Genetic Testing in Living Donation and Kidney Transplantation Practice - Christie Thomas
10:30 a.m.	Preimplantation Genetic Testing for Monogenic Kidney Disease – Whitney Thompson
11:00 a.m.	Returning Genetic Results to Patients: Doctors as Genetic Counselors – Hila Milo Rasouly
Medication De	ebates in CKDRoom 6C
Moderators: M	olly Fisher, Matthew Sparks
9:30 a.m.	Gadolinium-Based Contrast Agents Are Safe for Use in CKD: Pro – Ali Abu-Alfa
9:50 a.m.	Gadolinium-Based Contrast Agents Are Safe for Use in CKD: Con – Ihab Wahba
10:10 a.m.	Proton-Pump Inhibitors Cause CKD: Pro – Linda Awdishu
10:30 a.m.	Proton-Pump Inhibitors Cause CKD: Con – Georges Nakhoul
	Nonsteroidal Anti-inflammatory Drugs Should Be Part of the Pain Management Armamentarium in CKD: Pro – Jade Teakell
11:10 a.m.	Nonsteroidal Anti-inflammatory Drugs Should Be Part of the Pain Management Armamentarium in CKD: Con – Wendy St. Peter
	agement of Hypertension: Novel Approaches and Therapies
	aul Drawz, Dana Miskulin
9:30 a.m.	Dosing for Antihypertensive Medications in Patients with Kidney Diseases: Does Timing Matter? – Tara Chang
10:00 a.m.	Almost a Decade after the SPRINT Trial: Where Are We Now with BP Targets in CKD? – Alfred Cheung
10:30 a.m.	Management of Orthostatic Hypotension: Changing the Paradigm – Cyndya Shibao
11:00 a.m.	BP Management in the Inpatient Setting – Timothy Anderson

Sunday, October 27, 9:30 a.m. – 11:30 a.m.

Transitions i	n Home DialysisRoom '
ASN thanks to	he ASN Home Dialysis Steering Committee for assistance with this session.
Moderators: (Osama El Shamy, Bradley Warady
9:30 a.m.	Transitions to and from Kidney Transplantation and Home Dialysis – Jeffrey Perl
10:00 a.m.	Pediatric Home Dialysis to Adult Home Dialysis – Cozumel Pruette
10:30 a.m.	Transitions between Home Dialysis Modalities: How Can We Improve? –
	Annie-Claire Nadeau-Fredette
11:00 a.m.	Improving Transitions from Home Dialysis to In-Center Dialysis –
	Karthik Tennankore

Diabetic Kidneys and Interorgan Cross-Talk......Room 6D

Moderators: Ana Konvalinka, Hetal Shah

9:30 a.m. Cardiorenal Cross-Talk in Diabetic Kidney Disease – Luigi Gnudi

10:00 a.m. Hematorenal Cross-Talk in Diabetic Kidney Disease:

Clonal Hematopoiesis of Indeterminate Potential – Tanika Kelly

10:30 a.m. **Lipids and Diabetic Kidney Disease** – Philipp Scherer

11:00 a.m. **Hepatorenal Cross-Talk in Diabetic Kidney Disease** – Anna Mae Diehl







Discover Your Professional Value with Phairify at ASN Kidney Week

As an ASN member, you gain complimentary access to Phairify's Physician Value Exchange. This powerful tool offers nephrology-specific compensation and productivity data, helping you make informed career decisions and advance your career. Benchmark your career, define your own terms, and anonymously share your preferences with employers, all while staying up-to-date with market trends.

Experience the product first-hand and network with the founding physicians behind this innovative product.

Learn more at Booth #733 in the Scientific Exposition

1

"Although it is hard to know at which point basic science discoveries will have an impact on patient care, the more we know, the more likely it is that the knowledge we produce can be translated into treatments."

María Castañeda-Bueno, PhD
Instituto Nacional de Ciencias Médicas y
Nutrición Salvador Zubirán
2024 Joseph V. Bonventre Career
Development Grant Recipient

The investigators funded by KidneyCure share your commitment to improving the lives of millions living with kidney diseases. María Castañeda-Bueno, PhD, who focuses on understanding the regulation of Na+ and K+ handling by the kidney, is determined to advance kidney physiology and mentor "the future generation of kidney scientists."

Your support is crucial to funding the diverse ideas that will progress our field.

Kidney©ure

Fund it. Find it.

Make a Difference

Use your phone's camera to scan the QR code. Or visit: www.kidneycure.org/donate



ASN Excellence In Patient Care

Empowering the Kidney Community

Excellence in Patient Care (EPC) is at the forefront of ASN's mission to transform kidney care. By uniting nephrologists, kidney care professionals, patient advocates and key partners, EPC fosters clinical leadership and drives impactful initiatives that address the most pressing clinical priorities:

- Acute Kidney Injury (AKI): AKINow advances prevention and treatment standards for AKI.
- Diabetic Kidney Disease: The Diabetic Kidney Disease Collaborative (DKD-C) addresses critical needs in diagnosis and treatment of people with DKD.
- Dialysis Access: Through Fostering Inclusivity in Dialysis Access (FinD), a leadership training program, and Transforming Dialysis Access Together (TDAT), EPC is defining nephrology training and addressing health care disparities.
- eGFR Diagnostic Excellence: The eGFR Toolkit promotes nationwide adoption of the race-free equation for kidney diseases.
- Emergency Preparedness: The Emergency Partnership Initiative (EPI) coordinates services to support kidney care professionals and patients during disasters.
- Emerging Pathogens & Vaccinations: Current and Emerging Threats (CET) and the Kidney Community Vaccination Collaborative (KCVC) equip the community to combat health threats.
- Glomerular Diseases: The Glomerular Diseases Collaborative (GD-C) promotes high quality care and enhances training and awareness.
- Home Dialysis: Augment Fellows training through the Home Dialysis Project (HDP) to improve knowledge and access to home dialysis.
- Infection Prevention: Project Firstline delivers innovative infection control education, while Human Factors Engineering optimizes practices specific to dialysis.

EPC's commitment extends to providing cutting-edge education and resources, including interactive learning modules and a comprehensive library of webinars.

For more information, scan this QR code:





Join EPC at Kidney Week to engage with our experts on the latest advancements in kidney care. For more information, visit epc.asn-online.org or scan the QR code.



Top Advocacy Victories in 2024

In 2024, ASN achieved significant milestones in kidney health advocacy, focusing on early intervention, transforming transplant processes, accelerating innovation, achieving equity, and bolstering the kidney health workforce. These victories underscore ASN's commitment to advancing kidney care, supporting patients, and influencing policy at the highest levels. Here are the key accomplishments:

⊘ INTERVENE EARLIER TO PREVENT, DIAGNOSE, COORDINATE CARE, AND EDUCATE

- · Increased Congressional awareness of kidney disease screening
- Called for the establishment of an Officer of Kidney Health and Transplantation
- Continued advocating for screening recommendation by USPSTF

TRANSFORM TRANSPLANT AND INCREASE ACCESS TO DONOR KIDNEYS

- Enshrined ASN advocacy in CMMI Increasing Organ Transplant Access (IOTA) Model
- Improved support for living donors through the Honor Our Living Donors (HOLD) Act and increased funding for the Living Organ Donor Reimbursement Program
- Secured the largest funding increase for the Organ Procurement Transplantation Network (OPTN) and OPTN Modernization Initiative
- Gained federal commitment to collect data on kidney transplant referrals and waitlisting
- Achieved reimbursement for compounded immunosuppressants widely used with pediatrics

ACCELERATE INNOVATION & EXPAND PATIENT CHOICE

- Established the Transforming Kidney Health Research panel to develop a comprehensive federal research plan
- Sustained federal funding for research and innovation through KidneyX, ARPA-H, and NIDDK
- Advanced the Kidney PATIENT Act to retain Medicare Part D coverage of phosphatelowering medications

ACHIEVE EQUITY & ELIMINATE DISPARITIES

- Secured the removal of race from the Kidney Donor Profile Index, better reflecting the likelihood of graft failure as well as the fact that that race is a social, not a biological, construct
- Enabled AKI patients to access home dialysis services
- Secured medically necessary oral health coverage for kidney failure patients
- · Assisted state-level advocates in expanding dialysis access for uninsured individuals
- Integrated the Health Care Justice Committee into ASN's policy efforts

O BOLSTER THE KIDNEY HEALTH WORKFORCE

- Called for Congress to stabilize the physician workforce through automatic payment adjustments, extending MACRA APM incentive payments, and expanding Medicare supported Graduate Medical Education positions
- Partnered with the American Nephrology Nurses Association to raise awareness about kidney diseases workforce challenges
- Urged KUH to reinstitute the Institutional Research Training Grant (T32) program and continue the KUH U2C-TL1 program
- Advocated for ACGME accreditation for transplant nephrology in partnership with AST

For real-time policy and advocacy updates, follow @ASNAdvocacy on X.














The Research, Discovery, and Innovation (RDI) department of the ASN Alliance for Kidney Health offers three programs that stimulate, accelerate, and support biomedical research and innovations for people with kidney diseases.

- KidneyCure encourages and supports the kidney research and education workforce through grants and fellowships to pre-doctoral through early-career researchers.
- Kidney Health Initiative accelerates biologics, devices, and drugs for people with kidney diseases through collaborations and convenings of the kidney innovation community.
- KidneyX is a partnership between ASN and the US
 Department of Health and Human Services that directs
 and supports innovations urgently needed by people
 with kidney diseases.







Join us for our presentation at the American Society of Nephrology's Kidney Week 2024:

Potential Approaches to Addressing the Autoimmunity in Autoimmune Glomerulonephritis

Saturday, October 26, 2024 1:00PM – 1:45PM

Exhibitor Spotlight Theater #2, Exhibit Hall B San Diego Convention Center, San Diego, CA

www.vrtx.com/en-us



We're driven to make a difference for people living with APOL1-mediated kidney disease (AMKD), autosomal dominant polycystic kidney disease (ADPKD) and IgA nephropathy (IgAN).

Visit us at **Booth #1729**

www.vrtx.com/en-us